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The study of molecular containers has a prominent place in the scientific 
literature with many applications, including drug reversal. The clinical use of the 
cyclodextrin based reversal agent Bridion
TM
 has greatly improved the post-
operative safety of patients who undergo surgery aided by NMBAs such as 
rocuronium.  
 Chapter 1 introduces molecular containers, CB[n], and reports the use of 
the acyclic CB[n] known as Calabadion 2 as a broad spectrum reversal agent for 
NMBAs in rats. It also proposes the potential use of molecular containers as 
reversal agents for the treatment of overdose of illicit drugs in the context of 
available therapies.  
 Chapter 2 establishes that Calabadion 2 displays good to high levels of 
selectivity toward the NMBAs rocuronium, vecuronium, and cisatracurium both 
in vitro and based on simulations designed to capture the essence of the biological 
  
system.  The excretion profile of Calabadion 2 after NMBA reversal in rats was 
studied by a 
1
H NMR assay. It is reported that more than 50% of Calabadion 2 is 
eliminated intact by the kidneys within 1 hour.  
 Chapter 3 establishes that CB[n] based molecular containers - Calabadion 
1, Calabadion 2, and CB[7] display higher affinities than p-sulfocalix[4]arene and 
HP-β-cyclodextrin toward a panel of illicit drugs for which there are currently no 
USFDA approved pharmacotherapies. Calabadion 2 but not CB[7] is able to 
ameliorate the hyperlocomotive activity of rats treated with methamphetamine.  
The excretion profile of fentanyl and Calabadion 1 post reversal in rats was 
studied by HPLC and 
1
HNMR. It is reported that on an average 24 % fentanyl and 
40% Calabadion 1 are eliminated by the kidneys within 1 hour.  
Chapter 4 discusses the synthesis and molecular recognition properties of 
three new acyclic CB[n] hosts IV-2a – IV-2c which incorporate alkyl linkers of 
varying lengths- ethyl, hexyl, and decyl; capping one end of Calabadion 1. These 
hosts were less water soluble than Calabadion 1 due to the loss of two sulfonate 
groups and did not undergo intermolecular self-association. However, the 
intramolecular self-inclusion of the alkyl linkers inside the cavity of these hosts 
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Chapter 1: Introduction to Molecular Containers and their 
Application in Drug Reversal 
1.1 Introduction. 
 Interactions formed between atoms or ions lead to chemical bonds such as 
covalent, ionic, or metallic bonds to form molecules or crystals. There can 
also be associations between molecules which cause them to assemble in 
specific ways- which is the realm of supramolecular chemistry. These 
interactions between molecules are called non-covalent interactions and 
consist of weaker forces than the chemical bond, such as ion-dipole 
interactions, hydrogen bonding, π-π interactions, and the hydrophobic effect. 
1 
Non-covalent interactions are widespread in natural systems and despite being 
individually orders of magnitude weaker than the chemical bond; they can 
collectively exert a significant influence over the properties of the system. In 
proteins and nucleic acids they are responsible for maintaining the three 
dimensional structure of macromolecules, and they form the basis for the 
recognition between enzyme-substrate, antibody-antigen, and hormone-
receptor pairs.
2
 The first synthetic systems with molecular recognition ability 
were designed by Pederson, Lehn, and Cram who made crown ethers and 
cryptands which bound alkali metal ions in their cavity and more complex 
molecular hosts which could encapsulate guest molecules within their 
structures through non-covalent interactions.
3
 Since their seminal work, the 







containers and their unique applications. This chapter discusses some of the 
most popular containers, with a focus on CB[n] and their therapeutic use as 
drug reversal agents.  
 
1.2 Molecular Containers.  
 Just like everyday containers, molecular containers hold and protect their 
cargo –except they do so at the molecular level. The container molecule is 
referred to as the molecular host and the cargo, generally a smaller molecule 
that is encapsulated within the structural cavity of the host, is called the guest. 
The chemical environment within the host cavity can be quite different from 
the environment outside (such as that of the solvent) and has the ability to 
stabilize and even alter the properties of the guest; including its pKa, 











Host-guest chemistry has led to exciting applications in molecular machines, 
sensors, catalysis, separation techniques, and the formulation, delivery and 
sequestration of drugs and other guests. Some well-known containers in the 
literature include crown ethers, calixarenes, cyclodextrins, and cucurbiturils 
(Figure I-I). 
 Crown ethers are polyethers arranged in the shape of a ring and were first 
reported by Pedersen in 1967.
3
 The oxygen atoms in their structure act as 
Lewis bases that bind to and stabilize alkali metal cations within the ring 
through ion-dipole interactions. The size of the ring can be synthetically 
varied to accommodate a range of cations with varying size and charge 
densities. Crown ethers have been used as phase transfer catalysts. Over the 
next few decades, much more complex molecular hosts have emerged in the 
literature with more sophisticated molecular recognition features. 
 For example, calixarenes are composed of phenols linked by methylene 
bridges at the meta position with bulky alkyl groups in the para position. This 
creates a bowl-shaped hydrophobic cavity that is able to bind hydrophobic 





have been studied for their use as ionophores for membrane transport, 
extractants, stationary phases, electrode ionophores and in optical, 
electrochemical, biological sensing applications.
5
 
 Cyclodextrins (CDs) are currently the most widely used molecular 
containers for commercial applications.
6
 CDs are water soluble hosts made of 











). They have been classified as “generally 
recognized as safe” (GRAS) by the United Sates Food and Drug 
Administration (USFDA), and can be synthesized in various sizes (α = 6 sugar 
units, β = 7 sugar units, δ = 8 sugar units) and with varied functionalization.  
Some CDs currently in the market include Captisol®, a functionalized β-CD 
used to formulate insoluble active pharmaceutical ingredients (APIs), 
Bridion® or Sugammadex a δ-CD used as a reversal agent for neuromuscular 
blocking agent (NMBA) rocuronium, and Febreze™ a household odor 
eliminator with HP-β-CD as the active ingredient.   
1.3 Introduction to Cucurbit[n]urils. 
 Over the last two decades, a newer class of containers called 
cucurbit[n]urils (CB[n], n = number of glycoluril units) has gained the 
attention of chemists.
7
 Their outstanding molecular recognition ability far 











CB[n] are composed of glycoluril units linked together by methylene 
bridges to form closed rings. They were synthesized for the first time in 1905 
by Behrend and co-workers. The resulting material of unknown structure 
came to be known as “Behrend’s Polymer,” and was recrystallized from 
sulfuric acid, to give a white crystalline product. Behrend’s Polymer was 












Scheme I-1. Synthesis and structure of CB[n]. 
 
It was only in 1981 that Mock et al. elucidated the structure of this 
molecule by X-ray crystallography as cucurbit[6]uril, consisting of 6 
glycoluril units linked by 12 methylene bridges (Scheme I-1). The highly 
symmetrical molecule had a pumpkin-like shape and was named 
“cucurbituril” after the Latin name for the gourd family-cucurbitaceae.
10
 
Since then several research groups have worked towards the synthesis and 











  has led to the synthesis of CB[5], CB[6], 
CB[7], CB[8], CB[10], and CB[14]. The Day and Isaacs groups have 




  There are a few different structural features of the CB[n] family 
which contribute to its unprecedented molecular recognition ability. The 
cavity of CB[n] (lined with methine groups) is hydrophobic and is well suited 







in water by the hydrophobic effect. Additionally, the inclusion of a 
hydrophobic guest within the host cavity expels high energy water molecules 
previously occupying the cavity (in aqueous solution) further stabilizing to the 
complex. In contrast to the cavity, the CB[n] portal is lined with 
electrostatically negative carbonyl groups which stabilize the cationic (such as 
ammonium groups) parts of the guest, when they are appropriately positioned 
for ion-dipole interaction. The host structure is relatively rigid, making size 
and shape complementarity necessary for guest inclusion.
17
 Figure I-2a 
illustrates these interactions between CB[6] and guest I-1. The Ka for this 






 The height of CB[n] homologues is uniformly 9.1 Å, and therefore 
having six carbon atoms as linker positions the ammonium groups in I-1 at the 
appropriate distance from the two portals to benefit from ion-dipole 
interactions.  
 
Figure I-2. a) Structure of CB[6]•I-1 complex, and b) structures of some 








While cavity depth is constant across CB[n] homologues, cavity volumes 
and diameters increase systematically with the increase in n, which is the 
number of glycoluril units.
17
 CB[5] has the smallest cavity with a volume of 
68 Å
3
 which makes it an appropriately sized host for small gases such as Kr, 
CO2, CO, O2, and N2, and organic solvents such as methanol and 
acetonitrile.
19
 CB[6] is larger (142 Å
3
) and shows high affinity for guest I-1 




), but its volume can just about accommodate the 
larger guest I-2 (Ka = (550 ± 30 M
-1
), upon heating. Still larger adamantyl 
guests such as I-3 and I-4 cannot be included within CB[6]. However, CB[7] 
with a volume of 242 Å
3 




). The larger guest I-4 packs more tightly into the larger (367 Å
3
) cavity of 




) as compared to CB[7] where it can only 




). Table I-1 summarizes the 
Ka values of guests I-1 – I4 toward CB[6], CB[7], and CB[8].
18
  




Guest CB[6] CB[7] CB[8] 
I-1 (4.49 ± 0.84) × 10
8
 (8.97 ± 1.43) × 10
7
  - 
I-2 (550 ± 30 (1.84 ± 0.34) × 10
9
 - 
I-3 - (4.23 ± 1.00) × 10
12
 (8.19 ± 1.75) × 10
8
 
I-4 - (2.50 ± 0.39) × 10
4
 (4.33 ± 1.11) × 10
11
 









In 2014, the Isaacs group published a CB[7]-diadamantane guest (I-5) 












optimal packing, 14 ion-dipole interactions, and desolvation of the CB[7] 
portal in the complex and the resultant thermodynamic stabilization 
demonstrated the scope of optimizing host-guest interactions to meet and 
exceed affinities compared to their biological counterparts.   
CB[8] with an even larger cavity volume could further expand the scope 
of high affinity host-guest complexes and even forms ternary complexes with 
two identical or different guests.
21
 However applications of CB[8], especially 
in biological systems are severely limited by its poor (< 50 μM) aqueous 
solubility which is ascribed to its extensive self–association through CH•••O 
hydrogen bonding between methine protons of one CB[8] molecule with the 
ureidyl carbonyl portal of another.
22,23
 CB[10] is also insoluble in water, 
whereas CB[14] has a 360° twisted cavity; neither are suitable for 
encapsulation of biologically relevant molecules.  
There is a need for improving the properties of CB[n] such as aqueous 
solubility, facile synthesis, and incorporation of additional recognition 
features while retaining their impressive molecular recognition features. Thus, 
research in CB[n] field has branched out to functionalization approaches to 








1.4 Functionalization of Cucurbit[n]urils and Development of Acyclic 
Analogues.  
 Syntheses of functionalized derivatives of cyclic CB[n] have involved the 
use of the following strategies: (a) homomeric/ heteromeric cyclization of 
functionalized glycolurils with formaldehyde to obtain fully or partially 
functionalized CB[5] and CB[6] (Scheme I-2), (b) direct functionalization of 
preformed CB[n] to give mono and fully functionalized (n=5-8) derivatives 
(Scheme I-3), and (c) the building block approach using glycoluril oligomers 
to give monofunctionalized CB[n] (n = 6-8) (Scheme I-4).  
 
Scheme I-2. Synthesis of Me10CB[5] from I-6 and formaldehyde. 
  
The first fully characterized functionalized derivative of CB[n]-
decamethylcucurbit[5]uril (Me10CB[5]) was reported by the Stoddart group in 
1992.
24
 It was synthesized by the homomeric cyclization of dimethylglycoluril 
with formaldehyde in hydrochloric acid and water (Scheme I-2). The 
cyclization approaches from functionalized glycolurils have succeeded in 
improving the solubility of CB[6] derivatives in water and organic 
solvents.
25,26







smaller CB[n] homologues, CB[5] and CB[6] due to 1,5-diaxial interactions 
between substituents on adjacent glycoluril rings that comprise the methylene 
bridged eight-membered rings. Such 1, 5-diaxial interactions are expected to 
increase as the size of the CB[n] increases. 
27
This issue can be circumvented 
by starting with preformed CB[n] including CB[7] and CB[8]. The direct 
hydroxylation of CB[n=5-8] with K2S2O8 was introduced by Kim in 2003.
28
 
Scheme I-3. Synthesis of mono and fully hydroxylated CB[n].  
 
The resulting fully hydroxylated CB[n] could be modified to provide tailored 
CB[n] derivatives with different functional groups, frequently accompanied 
by enhanced solubility in common organic solvents.  
Monofunctionalized CB[n] present an exciting advance in the CB[n] field 
as they give more regiochemical control for further modifications. In 2011, 
the Isaacs group reported the templated synthesis of the glycoluril hexamer (I-
7)
29
 which led to the synthesis of the first monofunctionalized CB[7] with 
enhanced aqueous solubility in 2012.
30
  Monofunctionalized CB[7] has been 
used for targeted delivery application
31-33
 and covalently attached to Fujita 
type cages for stimuli responsive drug release.
34







enhanced aqueous solubility was also synthesized in a later work using a 
related strategy (Scheme I-4).
35
  
 In 2015 Bardelang and co-workers reported a direct photochemical 
monohydroxylation of CB[n] (n = 5- 8) using hydrogen peroxide in one step 
under mild reaction conditions.
36
 Functionalization approaches for closed 
CB[n] have led to improved solubilities of CB[6] and CB[8], improved ease 
of synthesis and purification, and the ability to chemically attach CB[n] to 
various scaffolds.  
 
Scheme I-4. Templated synthesis of hexamer (I-7) and building-block synthesis 







 Simultaneous development of water soluble acyclic CB[n] analogues, 
most notably by Isaacs and co-workers has opened up new avenues in CB[n] 
modification. The first acyclic congener of CB[6] was reported by the Isaacs 
group in 2003 (Scheme I-5a).
37
 Compound I-11 was synthesized by the 
alkylation of functionalized glycoluril (I-10) to introduce an ortho-xylelene 
linker, circumventing the difficulties in CB[6] synthesis. Carboxylic acid 
groups were incorporated on the convex face of the structure to improve 
water-solubility. Remarkably, the C-shaped preorganized compound I-11 
showed recognition properties towards alkyldiammonium ions similar to 
CB[6], with only a  moderate reduction in affinity.  
 
Scheme I-5. Synthesis of acyclic CB[n] congeners: a) I-11, and b) I-12.  
 
This was followed by the development of compound I-12 by Sindelar, which 
retained the glycoluril trimer backbone while incorporating aromatic walls.
38
 
Compound I-12 was able to bind bispyridinium ethylene and methylviologen 











synthesis and study of molecular clips and glycoluril oligomers, Isaacs and co-
workers recognized the importance of the carbonyl portal in CB[n] 
recognition. This led to the design of compound I-14, with a glycoluril 
tetramer backbone and aromatic walls with carboxylic acid groups to facilitate 
aqueous solubility (Scheme I-6).
39
 The affinity of host I-14 towards dialkyl 
ammonium, adamantyl ammonium, and aromatic ammonium guests was 








Scheme I-6. Building block synthesis of: a) glycoluril tetramer precursor (I-
13), b) acyclic CB[n] congener I-14, c) Calabadion 1 (I-15), and d) 







A further modification to the design of I-14, involved the replacement of the 
carboxylic acid groups by sulfonate groups to obtain Calabadion 1 (I-15). The 
solubility of I-15 was 346 mM in water and 105 mM in phosphate buffer (pH 
7.4) which is significantly higher than either CB[7] (20-30 mM) or compound 
I-14 (1-2 mM). Calabadion 2 (I-16) was designed by incorporating 
naphthalene walls in place of the benzene walls of Calabadion 1, and its 
solubility in water and buffer was 18 mM and 14 mM, respectively. 
Compounds I-15 and I-16 demonstrated excellent affinity towards poorly 
water soluble active pharmaceutical ingredients (APIs) and were able to 
increase their bioavailability in mice by acting as solubilizing agents.
40
 While 
I-16 has lower inherent water solubility than I-15, its larger aromatic walls 
allowed it to enhance the solubility of insoluble drugs at lower concentrations. 
Compounds I-15 and I-16 have also been reported as solubilizing agents for 
single walled carbon nanotubes (SWNTs) at 1000 times lower concentrations 
than surfactants while maintaining their optical properties,
41
 and as hosts for 
hydrocarbons for their uptake into water for potential application in 




The enhanced aqueous solubility and comparable or in some cases 
improved affinities of the Calabadion hosts (when compared to the cyclic 
CB[n]) prompted the Isaacs group to carry out numerous structural 
modifications to them in order to better understand the structure-affinity 











 length of the alkyl arm,
45
 and size of the glycoluril 
backbone.
46,47
 Chapter 4 discusses the effect of introducing alkyl linkers of 
varying sizes to Calabadion 1.  
 Another application of I-16 was reported in 2012. It was found that I-16 







, and reverses their effects in vivo.
48
 The application of 
molecular containers as reversal agents for different classes of drugs is 
described in detail in the following section.  
1.5 Drug Reversal Using Molecular Containers. 
 As described in the previous sections, molecular containers can alter the 
property of the guest encapsulated within their cavities. The biological activity 
of a drug is one such property. A drug exhibits its activity in the free state, 
however when it is completely bound within the cavity of a host, it can lose its 




Scheme I-7. Schematic representation of drug reversal by encapsulation 
within a molecular container. 
 
This effect can be used to sequester drugs in vivo whose activity is no longer 
desired. Factors such as the relative binding affinity between drug•container 







binding sites on biological receptor, and the selectivity of the container toward 
the drug relative to other molecules in the system play a role in determining 
the feasibility of this reversal. Sections 1.5.1 and 1.5.2 discuss the scope for 
using molecular containers as reversal agents for two different classes of 
drugs- NMBAs and drugs of abuse respectively.  
 1.5.1 Reversal of Neuromuscular Blocking Agents. 
  Annually, more than 400 million patients receive curare-type NMBAs 
during surgical procedures in operating rooms, intensive care units, and 
emergency medicine departments.
49
 NMBAs such as rocuronium and 
cisatracurium are often used as an essential adjunct to general anesthesia to block 
neuromuscular transmission (muscle relaxation) dose-dependently. This facilitates 
endotracheal intubation, optimizes surgical conditions, prevents potentially 
harmful movements during surgery, and also requires that the patient be put on 
mechanical ventilation. To speed up the recovery of the muscle function of the 
patient and to prevent residual neuromuscular block, it is often necessary to 
reverse the biological effect of NMBAs at the end of the surgery.
50,51
   This can be 
achieved by a few different mechanisms: (1) natural metabolism / excretion of the 
NMBA, (2) displacement of the NMBA from the acetylcholine receptor (AChR) 
by an increased local acetylcholine (ACh) concentration resulting from the 
inhibition of acetylcholine esterase (AChE) by drugs such as neostigmine, or (3) 
the encapsulation of the NMBA by a molecular container (Figure I-3). The first 







neuromuscular blockade. This results in muscle spasms and breathing problems in 
the patient from incomplete reversal, leading to increased healthcare costs from 
readmission to ICU and in some cases, mortality.
  
In the second mechanism, there 
can be cardiovascular side-effects from neostigmine itself due to an agonistic 
effect at muscarinic acetylcholine receptor (mAChR) and may even induce a 
(depolarizing) neuromuscular block via agonistic effects at nicotinergic receptors 
(nAChR).
52
 Hence this mechanism also does not improve respiratory safety. 
 
Figure I-3. Schematic representation of the onset and reversal of neuromuscular 
blockade. 
 
A major advance in the clinical practice of anesthesia was made by the 
introduction of a γ-cyclodextrin-derived molecular container known as 
Sugammadex, marketed as Bridion
TM
 by Merck with sales of more than $340 





) in water and reverses the effects of rocuronium in vivo.
53-55
  







bloodstream, thereby depleting its concentration at the neuromuscular junction.
56
  
The Sugammadex•rocuronium complex is subsequently excreted in the urine. 
Sugammadex has had a major impact on the clinical practice of anesthesia in 
Europe since it came into use in 2008. Its use in the United States was delayed by 
the US FDA because of hypersensitivity events, but the drug was approved for 
clinical use in 2015.
57-59
 While Sugammadex is able to reverse steroidal NMBAs 
such and rocuronium, it is not useful for reversing benzylisoquinolinium NMBAs 
such as cisatracurium due to weak binding affinity. As a result, there is a real need 
to develop alternative classes of molecular containers that function as reversal 
agents for the full range of clinically important NMBAs.   
Given the high Ka values typically observed for CB[n] for alkyl 
ammonium guests,
18
 their low toxicity
60
 and ability to cross cell membranes ,
61
 
CB[n]-type receptors represent a potential alternative to the γ-cyclodextrin 
derivative Sugammadex for the reversal of neuromuscular block. Among the 
known CB[n], only CB[8] and CB[10] are large enough to encapsulate the 
steroidal nucleus of NMBAs like rocuronium, but unfortunately the water 
solubility of these containers is poor (<50 μM) which severely limits their 
potential to function as in vivo reversal agents for NMBAs. Conversely, water-
soluble CB[7] is neither voluminous enough to encapsulate the steroidal ring 
system nor is its C=O···O=C distance of ~ 6.1 Å appropriate to electrostatically 
complement the N···N separation (~ 11.0 Å) of the steroidal NMBAs rocuronium 
and vecuronium.  In fact, Macartney has shown that CB[7] binds to the 







addition to this, CB[7] has poor selectivity for NMBAs compared to acetylcholine 
which implies that it could preferentially bind ACh instead of NMBA in vivo, 




Figure I-4. Chemical structures of molecular containers CB[7], Calabadion 2 (I-
16), Sugammadex, and guests rocuronium, vecuronium, cisatracurium, and 
acetylcholine. 
 
In 2012, the Isaacs group reported that acyclic CB[n]-type receptor I-6 
binds steroidal NMBAs 100-fold stronger and the benzylisoquinoline type NMBA 
cisatracurium 1000-fold stronger than Sugammadex in water (Table I-2.).
48
 In 
vivo experiments in rats showed that I-16 reverses deep neuromuscular blockade 











Table I-2. Binding constants (Ka, M
-1
) for the host–guest complexes formed in 
aqueous solution. 
Guest CB[7] Sugammadex Calabadion 2 
Acetylcholine (7.0 ± 1.3) × 10
5
 - (1.8 ± 0.2) × 10
5
 
Cisatracurium - 4.89 × 10
3
 (4.8 ± 0.9) × 10
6
 
Vecuronium (2.2 ± 0.3) × 10
5
 5.72 × 10
6
 (1.6 ± 0.2) × 10
9
 
Rocuronium (1.5 ± 0.2) × 10
4
 1.79 × 10
7
 (3.4 ± 0.6) × 10
9
 
    
The same trend is observed for recovery of spontaneous breathing, which is also 
rapid with I-16 as compared to experiments using placebo or Sugammadex.
48
 
Unlike Sugammadex, Calabadion 2 (I-16) displays a high in vitro binding affinity 
towards cisatracurium and also causes the in vivo reversal of the 
benzylisoquinolinium NMBA cisatracurium.
63,64
 These previously published in 
vivo and in vitro results together indicate the potential of I-16 to act as a broad 
spectrum reversal agent of NMBAs.  However, there is the possibility that a 
patient who has been or is being treated with NMBAs during surgery may have 







surgically.  For example, many surgical patients are treated with a variety of other 
drugs including antibiotics, antihistamines, and antiarrhythmics.
65
 Accordingly, 
for the further development of I-16 it is important to assess whether the binding of 
I-16 toward rocuronium, vecuronium, or cisatracurium can be compromised by 
the presence of other drugs.  The toxicity or other adverse effects of the host 
molecule and / or the host•NMBA complex are also important considerations. 
Chapter 2 addresses these issues of selectivity of Calabadion 2 toward NMBAs 
relative to other drugs and the pharmacokinetics of the excretion of container and 
drug in rats. 
  
 1.5.2 Reversal of Drugs of Abuse. 
 The recreational use of drugs of abuse is a major problem worldwide and 




For example, the 
Substance Abuse and Mental Health Services Administration (SAMHSA) 
estimated that 10.2% of the US population 12 and older (27 million) had used an 
illicit drug in the past month.
67 
Illicit drugs include methamphetamine, cocaine, 
marijuana, heroin, hallucinogens (ketamine, phencyclidine), inhalants, or 
prescription-type psychotherapeutics (pain relievers, tranquilizers, stimulants, and 
sedatives) when used non-medically (Figure I-4.).  
 







The heathcare costs of emergency room visits related to illicit drugs was ≈ $11 
billion in 2011 and overall costs associated with crime and lost work productivity 
was ≈ $193 billion.
68 
Accordingly, the treatments for illicit drug overdose and 
addiction is an important biomedical problem with significant socioeconomic 
consequences.  
Current treatments for drug overdose and addiction are based on either 
pharmacodynamic (PD) or pharmacokinetic (PK) strategies. PD strategies aim to 
disrupt the effects of the illicit drug at its site(s) of action (e.g. drug receptors) in 
the body. This approach is being used clinically for treating opioid overdose and 
addiction.
69
 Some examples of anti-opioid drugs that work by the PD strategy 
include: opioid receptor antagonists naloxone and naltrexone which are used to 
treat overdose and addiction; methadone, levomethadyl acetate (LAAM), and 
buprenorphine which are used to treat withdrawal; and non-opioid agents (such as 





While this treatment approach has been successful for opioids, 
there are currently no pharmacotherapies approved by the US FDA to treat 
cocaine, methamphetamine, or cannabis use disorders.
71
 In contrast, the PK 
strategy does not require a precise molecular level knowledge of the drug-receptor 
interaction needed in the PD strategy, but only the ability to decrease drug 
concentration below its effective concentration.
72
 For example, enzyme based 
therapeutics (e.g. human butyrylcholine esterase) are being explored that can 
hydrolyze cocaine into its inactive metabolites (ecgonine methyl ester and benzoic 







blood which results in a reduced concentration of the drug at its receptor in the 
brain.
69,73-75
 Immunotherapeutics are also being developed for cocaine, 
methamphetamine, and fentanyl, most notably by Janda,
76-79
 which act as 
peripheral blockers by binding and sequestering the “antigenic” drug and 





Figure I-5. Schematic representation of the pharmacokinetic and 
pharmacodynamic strategies for disrupting the effects of drugs of abuse. 
 
The PK strategy has also been implemented using synthetic molecular 
container compounds to directly compete with biological molecular recognition 
events for the reversal of NMBAs as outlined in section 1.5.1. However in the 









 have been reported for some amphetamine type molecules 
using phosphonate cavitands
83,84
 and CB[n] derivatives.
85
 Chapter 3 describes the 
recent work on the recognition properties of some common molecular containers 
towards a panel of frequently abused drugs. The in vivo reversal of 
methamphetamine by Calabadion 2 is reported as well as the pharmacokinetics of 








Chapter 2: Calabadion 2 as a Reversal Agent for 
Neuromuscular Blocking Agents   
The work presented in this chapter was take from Ganapati, S.; Zavalij, P. Y.; 
Eikermann, M.; Isaacs, L., In Vitro Selectivity of an Acyclic Cucurbit[n]uril 
Molecular Container towards Neuromuscular Blocking Agents Relative to 
Commonly Used Drugs. Org. Biomol. Chem. 2016, 14, 1277-1287 and Haerter, 
F.; Simons, J. C. P.; Foerster, U.; Moreno Duarte, I.; Diaz-Gil, D.; Ganapati, S.; 
Eikermann-Haerter, K.; Ayata, C.; Zhang, B.; Blobner, M.; Isaacs, L.; Eikermann, 
M., Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-
depolarizing Neuromuscular-blocking Agents. Anesthesiology 2015, 123, 1337-
1349. 
2.1 Introduction. 
Muscle relaxant drugs such as rocuronium, vecuronium (steroidal 
neuromuscular blocking agents- NMBAs) and cisatracurium 
(benzylisoquinolinium NMBA) are widely used pre-surgically to block the 
patients muscle function and optimize surgical conditions.
49
 Post-surgical 
reversal of neuromuscular blockade through the use of AChE inhibitors such as 
neostigmine is not optimal due to side effects arising from incomplete reversal of 
NMBAs and cardiovascular issues.
52
 The γ-cyclodextrin based molecular 
container- II-1 marketed by Merck as Bridion
TM 
has greatly improved the safety 
of NMBA reversal for rocuronium and vecuronium in Europe, and has recently 







concerns regarding hypersensitivity were addressed in clinical trials.
57,59
 Isaacs et 
al. have designed and synthesized the acyclic CB[n] based container II-2, which 
has shown faster reversal of steroidal NMBAs such as rocuronium and 
vecuronium. Container II-2 also shows a broader scope and also reverses the 
structurally distinct benzylisoquinolinium NMBA cisatracurium. The faster rate 
of reversal and broader scope can both be attributed to the order(s) of magnitude 
higher Kas shown by II-2 toward these three NMBAs compared to II-1.
48
 For the 
further development of II-2 as a broad spectrum reversal agent for NMBAs in the 
clinic, we have addressed two important issues in this chapter: (1) the in vitro 
selectivity of II-2 toward different NMBAs in the presence of other drugs 
commonly found on anesthesia trays in hospitals and (2) the pharmacokinetic 
profile of II-2 after NMBA reversal in rat urine. 
2.2 In Vitro Selectivity of Calabadion 2 towards Neuromuscular Blocking 
Agents Relative to Commonly Used Drugs. 
The superior Kas and faster / broader scope of in vivo reversal of NMBAs 
by II-2 compared with II-1 is a promising preliminary result for its development 
for clinical use. However, there is the possibility that a patient who has been or is 
being treated with NMBAs during surgery may have previously taken other drugs 
and/or need to be treated with other drugs post-surgically.  For example, many 
surgical patients are treated with a variety of other drugs including antibiotics, 
antihistamines, and antiarrhythmics.
65
Accordingly, for the further development 







vecuronium, or cisatracurium can be compromised by the presence of other 
drugs.   
 
Figure II-1. Chemical structures of CB[n], Sugammadex (II-1), Cb 2 (II-2); and 
NMBAs cisatracurium, rocuronium, vecuronium. 
In this study, we determine the binding constant of II-2 toward 27 drugs 
that are commonly used during and after surgery. We use the experimentally 
determined values of Ka and used them as known inputs to explore by 
simulations (Gepasi
TM
) the behavior of the multicomponent system comprising 
II-2, rocuronium or vecuronium or cisatracurium, acetylcholine receptor (AChR), 
and drug using estimated or known values of clinical drug concentration ranges 
and AChR binding constants.   
Thus we assessed the potential for these 27 drugs to induce displacement of 
rocuronium, vecuronium, or cisatracurium from the cavity of II-2. The results of 
these simulations are presented in the form of three dimensional plots that connect 
the Ka of the II-2•drug complex and the dosage of drug with the equilibrium 
concentration of the AChR•NMBA complex. These drugs were selected to 







etc. which are typically present on standard anesthesia trays at hospitals.  Cationic 
drugs were selected specifically as they are expected to have higher affinity 
towards our anionic acyclic CB[n]-type container II-2, and therefore pose the 
highest potential for displacing NMBAs from the II-2•NMBA complexes.  
 








 2.2.1 Binding Properties of II-2 towards Drugs II-3 – II-29 Investigated by 
1
H NMR. 
Initially, we investigated the ability of container II-2 to bind drugs II-3 – 
II-29 by 
1
H NMR spectroscopy.  For complexes between II-2 and drugs II-3 – II-
29 we commonly observed upfield shifting of guest resonances which indicates 
that these protons on the guest (drug) are located in the cavity of II-2.  All of the 
II-2•drug complexes display intermediate to fast kinetics of exchange on the 
1
H 
NMR timescale.   
These preliminary 
1
H NMR observations suggested that complexes 
between container II-2 and drugs II-3 – II-29 would be of moderate stability in 
water. In contrast, complexes between II-2 and NMBAs cisatracurium, 
rocuronium and vecuronium exhibit slow exchange on the chemical shift 
timescale. To facilitate further discussion of the NMR results we present the 
1
H 
NMR spectra recorded for II-26 (procaine), II-2, the II-2•II-26 complex, and a 
mixture of II-2•II-26 with excess II-26 present (Figure II-3).  These 
1
H NMR 
spectra display a number of interesting features, which provide insight the nature 
of the II-2•II-26 complex. For example, the aromatic peaks He, and Hf of II-26 
shift considerably upfield (> 1 ppm) upon binding to one equivalent of II-2 
(Figure II-3c). This dramatic upfield shift reflects the anisotropic shielding 
environment provided by the two aromatic naphthalene sidewalls of II-2.  Given 
the aromatic nature of drug II-26, we surmise that π-π interactions are formed 







26 to one equivalent of II-2 (Figure II-3d) He and Hf shift back downfield 
(relative to Figure II-3c) to a position that is the average of the completely bound 
and completely free form of II-26. This indicates a fast kinetics of exchange 
between free guest II-26 and the II-2•II-26 complex relative to the 
1
H NMR 




H NMR spectra recorded (400 MHz, RT, 20 mM NaH2PO4 buffered 
D2O, pH = 7.4) for a) II-26, b) II-2, c) an equimolar mixture of II-2 and II-26 








 In contrast, the aromatic protons Hu and Hv of host II-2 undergo a 
downfield shift (Hu, 7.72 ppm; Hv, 7.17 ppm) upon formation of the II-2•II-26 
complex.  The observed downfield shift is due to the disruption of edge-to-face 
π-π interactions between the tips of free host II-2 which are disrupted upon 
formation of the II-2•II-26 complex.  Addition of a second equivalent of II-26 
results in little additional shifting and sharpening of the resonances for Hu and Hv 
because the II-2•II-26 complex is largely formed at both stoichiometries.   
Interestingly, the resonances for Ha, Hb, and Hc of 2-diethylaminoethyl 
sidechain also show significant upfield shifts upon binding to II-2 which is 
probably reflects partial inclusion of the sidechain in the shielding region defined 
by the glycoluril tetramer backbone and the aromatic naphthalene sidewalls.  
Analogous phenomena were seen in the 
1
H NMR spectra recorded for the 
remaining II-2•drug complexes in accord with the previously established 
preferences of CB[n]-type receptors to bind the hydrophobic portions of guests 
within the hydrophobic cavity whereas the cationic ammonium groups reside at 
the ureidyl carbonyl portals and benefit from ion-dipole interactions.
86,18  
 2.2.2 Stoichiometry of the Complexes between II-2 and Drugs II-3 – 
II-29.   
It is well known that CB[n]-type receptors generally form host•guest 
complexes with 1:1 stoichiometry.  In order to confirm the 1:1 stoichiometry of 









Figure II-4. Job plot constructed for mixtures of II-2 and II-26 ([II-2] + [II-26] = 
1 mM) by monitoring the change in 
1
H NMR (400 MHz, RT, 20 mM NaH2PO4 
buffered D2O, pH = 7.4) chemical shift of Hu (7.72 ppm) of II-2. 
 
In Job plots, a series of samples containing host and guest at a constant 
total concentration ([host] + [guest] = constant) are prepared and are investigated 
by an appropriate spectroscopic technique.  A plot of the change in spectroscopic 
signal versus mole fraction displays a maximum at the mole fraction that 
corresponds to the stoichiometry of the host•guest complex.  Figure II-4 shows 
the Job plot constructed using II-2 and II-26 at a total concentration of 1 mM.  
The Job plot displays a maximum at a mole fraction of 0.5 which confirms the 1:1 
stoichiometry of the II-2•II-26 complex.  Job plots were constructed for several 







2.2.3 X-ray Crystal Structure of the II-2•II-29 Complex.   
We were fortunate to obtain single crystals of the II-2•II-29 complex by 
slow evaporation of an aqueous solution of the complex and to solve its x-ray 
crystal structure.   
 
Figure II-5.  Cross-eyed stereoscopic representation of the geometry of one 
molecule of II-2•II-29 from the x-ray crystal structure.  Color code: C, grey; H, 
white; N, blue; O, red; S, yellow; hydrogen bond, red–yellow striped. 
Figure II-5 shows a cross-eyed stereoview of one molecule of II-2•II-29 in the 
crystal which displays a number of interesting features. As described previously, 
the glycoluril tetramer backbone of II-2 imparts an overall C-shape to the 
receptor whereas the terminal naphthalene sidewalls help to define a hydrophobic 
box-like cavity.  Interestingly, host II-2 within the II-2•II-29 complex adopts a 
helical (chiral) conformation where the two naphthalene sidewalls are splayed 
out-of-plane with respect to the glycoluril tetramer backbone; both senses of 
handedness are observed in the crystal in a 1:1 ratio.  Furthermore, the ammonium 
ion unit of guest II-29 engages in an N-H•••O=C hydrogen bond (N•••O distance 







enclosed within the cavity of II-2 but does not engage in π-π stacking interactions 
with naphthalene sidewalls.  In addition, one of the amidine N-H groups at the 
opposite carbonyl portal appears to engage in a weak hydrogen bond (N•••O 
distance = 3.231 Å; N-H•••O angle = 147.2˚)   
 
Figure II-6. Cross-eyed stereoscopic representation of the packing of II-2•II-29 
in the x-ray crystal structure.  Color code: C, grey; H, white; N, blue; O, red; S, 
yellow. 
 
Finally, Figure II-5 shows that the naphthalene sidewalls of II-2 in the II-
2•II-29 complex do not undergo edge-to-face π-π interactions which is in accord 
with the downfield shift observed for Hu and Hv upon complex formation.
48,44
 The 
three dimensional packing of the individual molecules of II-2•II-29 complex in 
the crystal is also intriguing (Figure II-6).  As shown in Figure II-6, two 
molecules of the II-2•II-29 complex of the same helicity pack next to one another 
by interactions between the convex faces of the aromatic sidewalls (marked with 
@ symbol).  Additional homochiral pairs of the II-2•II-29 complex extend along 







the II-2•II-29 complex are held together by reciprocal pairs of close CH•••π 
interactions (CH•••π distance = 2.798, 2.868 Å; CH•••π angle = 161.7˚, 149.1˚) 
between molecules of complex II-2•II-29 of opposite helicity. 
 2.2.4 Measurement of Kas between II-2 and Drugs II-3 – II-29.  
After having established the inclusion binding of drugs II-3 – II-29 inside 
container II-2 by 
1
H NMR spectroscopy, we decided to measure the binding 
affinity (Ka, M
-1
) for the II-2•II-3 – II-2•II-29 complexes. For this purpose, we 
employed three different strategies: (1) direct UV/Vis titrations (for UV/Vis 
active drug II-4), (2) direct 
1
H NMR titrations (for drugs II-3, II-5 – II-7, II-9, 
II-11, and II-13 with Ka < 5000 M
-1
), and (3) UV/Vis competition titrations (for 
UV/Vis inactive drugs with Ka > 5000 M
-1
).  The detailed procedures and models 
used to analyze the data using Scientist
TM
 are given in Appendix 1. For example, 
Figure II-7a shows the 
1
H NMR spectra recorded during the titration of a fixed 
concentration of II-2 (0.976 mM) with II-6 (0 – 6.57 mM).  As described above, 
upon formation of the II-2•guest complexes, we generally observe a downfield 
shift of Hu and Hv because the tips of the naphthalene sidewalls are no longer 
engaged in edge-to-face π-π interactions.  Figure II-7b shows a plot of chemical 
shift of Hv versus [II-6] which was fitted to a standard 1:1 binding model using 
Scientist
TM





 for the II-2•II-6 complex.  Similar 
1
H NMR titrations were performed for guests 
II-3, II-5 – II-7, II-9, II-11, and II-13 (Appendix 1) and the results are presented 








Figure II-7.  a) 
1
H NMR (400 MHz) stack plot of the titration of  II-2 
(0.976 mM) with guest II-6 (0 – 6.57 mM) in 20 mM NaH2PO4 buffered D2O (pH 
= 7.4); b) plot of the chemical shift of Hv as a function of guest concentration. The 







Next, to determine the Ka values for the stronger II-2•guest complexes we 
performed competition experiments monitored by UV/Vis spectroscopy.
87
 For 
this purpose, we employed Rhodamine 6G which undergoes significant changes 
in its UV/Vis spectrum upon formation of the II-2•Rhodamine 6G complex (Ka = 













Rhodamine 6G from the II-2•Rhodamine 6G complex and reverse the observed 
UV/Vis changes.   
 
 
Figure II-8.  a) UV/Vis spectra recorded during the titration of a mixture of II-2 
(9.92 µM) and dye rhodamine 6G (10.0 µM) with guest II-28 (0 – 1.21 mM) in 
20 mM NaH2PO4 buffer (pH = 7.4), b) plot of absorbance at 550 nm as a function 
of the concentration of II-28. The solid line represents the best non-linear fit of 






Figure II-8 shows the absorbance data obtained from the competitive 
UV/Vis titration of II-2•Rhodamine 6G with II-28 (0 – 1.21 mM).  We fit a plot 





















input.  Analogous UV/Vis competition experiments were performed which 
allowed us to measure the remaining Ka values given in Table II-1.  For purposes 
of comparison, the Ka values for Sugammadex (II-1) toward drugs II-3 – II-29 as 
reported by Zwiers are also given in Table II-1.
65 
 
2.2.5 Commentary on the Tabulated Ka Values.   
An examination of the binding constants given in Table II-1 reveals that 









 for ranitidine II-29; 13 out of 27 drugs 








.     
Some of the trends can be readily understood given the well-known 
binding preferences of CB[n] and acyclic CB[n]-type receptors for hydrophobic 
and (di)cationic guests.
86,18





) we find neutral or anionic compounds like diclofenac (II-3), acetaminophen 
(II-8), chloramphenicol (II-9), and aminophylline (II-11) as well as highly 
hydrophilic and hydroxylated compounds like tetracycline (II-4), kanamycin (II-
6), doxycycline (II-13), and vancomycin (II-14).Other weak binders include the 
zwitterionic compounds amoxicillin (II-5) and cefepime (II-7). Conversely, 




) we find compounds that better satisfy 







Table II-1. Binding constants determined by direct or competitive UV/Vis assays 
or direct 
1
H NMR titrations for the interaction between II-2 and drugs II-3-II-29, 
drug dosages in the rat model, estimated plasma concentrations, and binding 
constants toward II-1. 
Drug Ka with II-2 (M
-1
) 















     
Acetylcholine 
chloride 
(1.8 ± 0.2) × 10
5 d)
 - - - 
Cisatracurium 
besylate 
(4.8 ± 0.9) × 10
6 d)





(1.6 ± 0.2) × 10
9 d)





(3.4 ± 0.6) × 10
9 d)
 3.5 160 1.79 × 10
7
 
II-3 (2.0 ± 0.4) × 10
3 a) 
10 763 2.50 × 10
4 
II-4 (2.3 ± 0.2) × 10
3 b)
 10-20 819 <1.00 × 10
3
 
II-5 (3.0 ± 0.4) × 10
3 a) 
10-20 997 <1.00 × 10
3 
II-6 (3.0 ± 0.6) × 10
3 a)
 10-20 752 <1.00 × 10
3
 
II-7 (4.6 ± 0.5) × 10
3 a)
 10-40 1040 <1.00 × 10
3 
II-8 (5.9 ± 0.5) × 10
3 c) 
100-300 32122 <1.00 × 10
3
 
II-9 (5.9 ± 1.8) × 10
3 a) 
45-80 4696 <1.00 × 10
3
 
II-10 (8.6 ± 0.8) × 10
3 c) 
0.5-1 63.1 <1.00 × 10
3
 
II-11 (1.4 ± 0.4) × 10
4 a) 
3-100 5948 <1.00 × 10
3
 
II-12 (2.1 ± 0.2) × 10
4 c) 
0.5-2 88.5 - 
II-13 (3.3 ± 1.0) × 10
4 a)
 5-10 355 2.40 × 10
4
 
II-14 (4.4 ± 0.3) × 10
4 c) 
20 335 1.78 × 10
4
 
II-15 (4.8 ± 0.3) × 10
4 c) 
20-40 1615 1.12 × 10
4
 
II-16 (8.3 ± 0.6) × 10
4 c)
 0.001 0.12 - 
II-17 (1.9 ± 0.1) × 10
5 c) 
6.25-12.5 709 1.02 × 10
4
 
II-18 (1.9 ± 0.1) × 10
5 c) 
0.018 1.67 <1.00 × 10
3
 
II-19 (2.5 ± 0.1) × 10
5 c) 
0.005-0.015 1.60 <1.00 × 10
3
 
II-20 (5.3 ± 0.4) × 10
5 c) 
0.2-0.4 9.60 2.44 × 10
4 
II-21 (5.9 ± 0.7) × 10
5 c) 
- - - 
II-22 (8.0 ± 0.7) × 10
5 c) 
0.01-0.1 3.04 1.84 × 10
4
 
II-23 (8.2 ± 0.9) × 10
5 c) 
20 1532 - 
II-24 (9.3 ± 0.9) × 10
5 c) 
0.1-0.3 18.2 <1.00 × 10
3
 
II-25 (9.7 ± 1.1) × 10
5 c) 
0.02-0.15 14.0 2.61 × 10
4
 
II-26 (9.8 ± 0.5) × 10
5 c) 
1-2 133 - 
II-27 (2.8 ± 0.1) × 10
6 c) 
 0.25-0.45 21.4 <1.00 × 10
3
 
II-28 (3.3 ± 0.5) × 10
6 c) 
0.02-0.05 1.22 <1.00 × 10
3
 
II-29 (4.5 ± 0.7) × 10
6 c) 
6-10 553 5.40 × 103 
 a) measured by direct 
1
H NMR titration.  b) measured by direct UV/Vis titration, 











For example, the two linear dications procaine (II-26) and suxmethonium 
chloride (II-27) are among the strongest binding drugs. In accord with the 
preference of CB[n]-type receptors for hydrophobic bicyclic and polycyclic 
cations,
19,86,18,89,90 
compounds like morphine (II-20), naloxone (II-22), atropine 
(II-28) are among the better binders for II-2.  Recently, we reported that II-2 is an 
outstanding solubilizing agent for insoluble drugs that are aromatic cations due to 
the formation of π-π interactions between the insoluble drug and the naphthalene 
walls of II-2 which define a hydrophobic box.
44
 The observed stronger binding 
between II-2 and aromatic ammonium ions dibucaine (II-21), propranolol (II-25), 
and imipramine (II-23) are consistent with the previously delineated binding 
preferences of II-2. 
 2.2.6 Assessment of the Potential for Displacement Interactions.   
 We undertook the measurement of the binding constants for the complexes 
between II-2 and drugs II-3 – II-29 with the goal of assessing the potential for 
these drugs to interfere with the in vivo use of II-2 as a reversal agent for 
neuromuscular block induced by rocuronium, vecuronium, or cisatracurium.  
Given the high level of complexity of the in vivo system (e.g. metabolism, 
excretion, biodistribution, other binding partners) we created a minimalist model 
that is amenable to appropriate simulations.  Figure II-9 shows the three equilibria 
that we decided to consider, namely the binding of NMBA to the acetylcholine 
(AChR) receptor and to Calabadion 2 as well as the binding of drug to Calabadion 







of NMBA, AChR and drug it is possible to calculate the concentrations of each 
species present at equilibrium.  It should be noted that the total concentration of 
displacing drug in this model represent an upper limit to what would be observed 
in vivo because drugs can also be bound to plasma proteins and are subject to 
rapid distribution to peripheral compartments such as the intercellular space. 
Accordingly, our model is a conservative screening technique that will generally 
overestimate the displacement potential of a given drug. Our goal of the 
simulations was to systematically explore the influence of the different Ka values 
and total concentrations on the equilibrium concentration of the AChR•NMBA 
complex since the occupation of the biological receptor by NMBA is ultimately 
what controls the biological function.  The simulations are meant to inform and 
serve as a stepping stone toward future in vivo selectivity experiments which will 
ultimately determine the selectivity of II-2 towards NMBAs over other drugs in 
the actual biological system. 
 









 2.2.7 Simulation of In Vivo Equilibria Using modelling Software 
Gepasi.   
 We decided to perform the simulations using the freely available software 
package Gepasi
91-93
 which is capable of performing both kinetic and 
thermodynamic simulations of user defined interaction networks.  The Gepasi 
software is very powerful and capable of performing multiple simulations where 
one or more variables are scanned sequentially (using the scan function), which 
allowed us to develop insight into the influence of each variable.  The equilibrium 
concentrations of each species determined by the Gepasi simulations were 
exported to and visualized using Microsoft Excel.  Below we present simulations 
using values derived from the data for rocuronium and cisatracurium.  An 
analogous simulation for vecuronium is presented in Appendix 1. 
2.2.8 In Vitro selectivity of Calabadion 2 for Rocuronium.   
 For the simulations using II-2, rocuronium, and drugs II- 3 – II-29 we 




) and K3 using the values in 
Table 1.  We set the total concentration of rocuronium equal to 160 μM to mimic 
the initial in vivo plasma concentration in the rat; this value was calculated based 
on the known dosage (3.5 mg kg
-1
, twice the ED90), the average mass (370 g) and 
the average plasma volume (15.2 mL) of the male Sprague-Dawley rats used in 
our previous experiments.
94
 The initial concentration of AChR was defined as 







shows a three dimensional plot of the mole fraction of AChR•Rocuronium (z–
axis) as a function of the total concentration of drug (e.g. II-3 – II-29, x-axis), and 
log K3 (y-axis) obtained from the simulations.   
 
 Figure II-10. Three dimensional surface plots of the concentration of 
AChR•NMBA at equilibrium versus log [Drug] and log K3 for II-2•Drug) for: a) 









; b) cisatracurium at [cisatracurium] = [AChR] = 18 








. The red dots 








The range of the x-axis from 0.1 μM to 100 mM was chosen to span the range of 
plasma concentrations of drug II-3 – II-29 given in Table II-1 whereas the range 






 was chosen to span the range of K3 values given 
in Table II-1 for drugs II-3 – II-29.  This surface plot represents the general 
behavior of [AChR•Rocuronium]equilibrium over the full range of dosages and K3 of 
potentially interfering drugs studied in this work. As can be readily seen, there is a 
plateau region in the lower left region of the plot that corresponds to situations 
where the drugs do not display any ability to displace rocuronium from the II-
2•rocuronium complex and therefore [AChR•rocuronium] is low.  
Conversely, as [Drug] and/or log K3 is increased the [AChR•rocuronium] 
increases.  The region in the upper right hand side of the plot corresponds to 
situations where drugs with these combinations of [Drug] and log K3 values are 
expected to display the ability to displace rocuronium from the II-2•rocuronium 
complex resulting in the increase in the concentration of AChR•rocuronium. The 
data points corresponding to the individual combinations of plasma 
concentrations and K3 values for each drug are marked on the 3D surface of 
Figure II-10a as red dots.  According to the constraints of this simulation, none of 
the drugs possess any substantial ability to displace rocuronium from II-
2•rocuronium.  From the shape of Figure II-10a, it is easy to see that drugs with a 
combination of a high value of K3 and a large dose are most likely to displace 







 2.2.9 In vitro selectivity of Calabadion 2 for Cisatracurium.  
 The binding affinity of II-2 toward the NMBA (K2) relative to potentially 
competing drugs plays a major role in influencing how much NMBA is bound to 










) and therefore we would expect that the potential for displacement of 
cisatracurium from the II-2•cistracurium complex by drugs II-3 – II-29 would be 
more significant than for rocuronium.  For the purpose of the simulations, we 
created a three dimensional plot of the equilibrium concentration of 
AChR•cisatracurium (z-axis) as a function of the concentration of the potentially 
interfering drug over a range of concentrations (1 μM – 100 mM, full range of 
average dosage of drugs II-3 – II-29, Table II-1, x-axis), and the change in K3 






 (range of Ka values measured for drugs II-3 – II-29 
with II-2, Table II-1, y-axis) as shown in Figure II-10b.  For this simulation, we 
fixed the total concentration of cisatracurium at 18.3 μM (Table II-1) and the 
concentration of Calabadion 2 at 1183 μM (64 equivalents) which is derived from 
our previous in vivo experiments which found that a dose of 80 mg kg
-1
 was 





 and [AChR] as 18.3 μM.  Figure II-10b represents the general behavior of 
[AChR•cisatracurium] over the full range of drug concentrations and K3 values of 
potentially interfering drugs studied in this work.  Similar to the case of 







displacement of cisatracurium from the II-2•cisatracurium complex is not 
significant.  The upper right side of the Figure II-10b is the region where both 
drug concentration and K3 are high and where the displacement of cisatracurium 
from the II-2•cisatracurium complex is most significant.  The data points 
corresponding to the individual concentrations and K3 values for each drug are 
marked on the 3D surface of Figure II-10b as red dots.  Once again, all of the 
drugs lie in the plateau region which indicates that they do not displace 
cisatracurium from the II-2•cisatracurium complex.  Simulations using lower 
doses of II-2 (32 or 16 equivalents) display higher equilibrium mole fractions of 
AChR•cisatracurium for drugs II-29 and II-23 (Appendix 1). Of course, the 
dramatic simplifications introduced into our model means that future in vivo 
experiments are needed to determine if drugs with high combinations of K3 and 
dosage (e.g. ranitidine (II-29) and imipramine (II-23)) nearby the edge of the 
plateau result in displacement of II-2•cisatracurium in practice. In this regard, it is 
worth mentioning that we previously found that the in vivo onset and duration of 





unaffected by prior treatment with II-2.
64
 Accordingly, the fact that a drug 
possesses a high K3 value toward II-2 is insufficient to conclude that undesirable 
displacement interactions will occur. 
 2.2.10 Influence of K1.   
 The simulations described above assessed the influence of a range of 











) that was not drawn from experimental 
data, but rather based on the known in vivo ability of II-2 to function as a reversal 
agent for rocuronium and cisatracurium. Accordingly, we thought it was 
important to study the influence of K1 on the equilibrium concentration of 
AChR•rocuronium.   
 
 
Figure II-11. Plot of the mole fraction of AChR•rocuronium versus log (K1) for 
drugs II-3 – II-19 present at their estimated plasma concentrations from Table II-
1.  a) [II-2]initial = 320 μM (2-fold higher than [Rocuronium]initial), and b) [2]initial = 



















, and [drug] and K3 are taken from Table II-1.  As can be readily seen, as 
K1 is increased the concentration of AChR•rocuronium increases because the 
difference in free energy between AChR•rocuronium and II-2•rocuronium 
decreases.  At high values of K1 the concentration of AChR•rocuronium is most 
significant for ranitidine (II-29).  The reason ranitidine possesses the highest 
potential to displace rocuronium from II-2•rocuronium to form II-2•II-29 is due 





also due to its high therapeutic dose (6-10 mg kg
-1
) which served as inputs to the 
simulation.   
Three other drugs that display significant amounts of AChR•rocuronium at 
high K1 values are II-23, II-17, and II-15 (Figure II-11a) which similarly possess 
a combination of moderate to large K3 and high therapeutic dose values.  Figure 
II-11b shows the simulation of the system when [II-2] is increased to 960 μM (6-
fold higher than rocuronium).  As can be seen, the concentration of 
AChR•rocuronium at equilibrium is decreased in all cases relative to Figure II-
11a.  However, the effect is most dramatic for compound II-29 which has the 
highest Ka value but the lowest therapeutic concentrations among II-29, II-23, II-
17 and II-15.  The excess of II-2 therefore sequesters more significant amounts of 
II-29 as its II-2•II-29 complex than is possible for II-23, II-17, and II-15 with 







(1) the potential for displacement of NMBA from the II-2•NMBA complex is 
reduced by maximizing the difference between K2 and K1, and (2) that the use of 
concentrations of II-2 at the level of the therapeutic concentration of the 
competing drug can be used to reduce displacement of the II-2•NMBA complex. 
 2.2.11 Influence of [AChR].   
 Lastly, in the simulations described above, we have somewhat arbitrarily 
fixed [AChR] as being equal to the concentration of NMBA.  Therefore, we 
decided to investigate the influence of [AChR] on [AChR•rocuronium] in the 
presence of ranitidine ([II-29] = 553 μM) by performing simulations with [AChR] 
spanning the 1.6 μM to 16000 μM range.  The other variables were fixed as 













.   
 








Figure II-12 shows plots of the mole fraction of AChR•rocuronium 
relative to [AChR] (left axis) and relative to [Rocuronium] (right axis) as a 
function of [AChR].  These two curves cross when [AChR] = [rocuronium] = 160 
μM.  At low [AChR] the mole fraction of AChR•rocuronium is ≈ 5%; as [AChR] 
increases beyond the fixed concentration of rocuronium (160 mM) the mole 
fraction of AChR•rocuronium drops by necessity.  Conversely, if [AChR] is high 
then the mole fraction of AChR•rocuronium increases because of Le Chateliers 
principle. 
 2.1.12 Summary 
 In summary, we measured the binding constants for the complexes 
between II-2 and drugs II-3 – II-29 by a combination of direct 
1
H NMR 
titrations, direct UV/Vis titrations, and competitive UV/Vis binding assays using 
the II-2•rhodamine 6G complex.  The binding constants range from 2000 M
-1
 (for 




 (for II-29).  The 1:1 stoichiometry of the complexes were 
confirmed by Job plots whereas the complexation induced changes in 
1
H NMR 
chemical shift were used to shed light on the geometry of selected II-2•drug 
complexes.  The x-ray crystal structure of the II-2•ranitidine complex showed: (1) 
the expected inclusion of the furan ring in the cavity of II-2, (2) the ammonium 
ion bound at the C=O portal, and (3) an end-to-end helical twist of the acyclic 
CB[n] receptor II-2.  Simulations were performed to assess the potential for drugs 
II-3 – II-29 to displace NMBA from the II-2•NMBA complex resulting in the 







possess high values of K3 and/or high therapeutic concentrations have the highest 
potential to display displacement interactions.  For rocuronium and vecuronium 
none of the drugs display significant displacement potential although ranitidine 
(II-29) should be assessed in future in vivo studies.  For cisatracurium, drugs II-
29 and II-23 display both high dose and high K3 and lie near the edge of the 
plateau in Figure II-10b and consequently must be closely evaluated in future in 
vivo studies.  The more significant potential for displacement seen in the 
cisatracurium simulations can be traced to fact that K2 for II-2•cisatracurium (K2 









).   
2.3 Renal Elimination of Calabadion 2 in Rats Post Reversal of 
Neuromuscular Blockade.  
An important issue in the development of II-2 as a reversal agent for 
NMBAs is establishing that it can be safely administered and gets eliminated 
rapidly without forming harmful metabolites. In vivo studies in Swiss Webster 
mice and Sprague-Dawley rats by the Briken and Eikermann groups respectively, 
have shown that II-2 displayed low cytotoxicity in 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium (MTS) based 
cell viability and adenylate kinase release cell necrosis assays, did not inhibit the 
human ether-à-go-go-related channel, and was not mutagenic (Ames test). A 
cumulative dose of 1.6g kg
-1
 (well above the therapeutic dose needed for NMBA 









proved to be well tolerated and nonlethal in adult male Sprague-Dawley 
rats.
48,64,95  
In the following study we describe the quantification of the urinary 
elimination of II-2 and rocuronium in Sprague-Dawley rats after compound II-2 
was used to reverse the neuromuscular blockade induced by rocuronium and 
cisatracurium. Our collaborator Professor Eikermann and co-workers at 
Massachusetts General Hospital injected Sprague Dawley rats with varying doses 
of II-2 to reverse rocuronium or cisatracurium induced NMB. One hour after 
administration of the reversal agent, all the urine was collected from the bladder 
of these rats, and stored at -80 °C. We designed a 
1
H NMR based assay to get a 
preliminary understanding of the pharmacokinetic profile of II-2. 
 2.3.1 
1
H NMR Based Assay for Quantification of II-2, Rocuronium, 
and II-2•rocuronium complex for Rocuronium Reversal Samples. 
When rocuronium binds within the cavity of II-2 in water, the steroidal 
skeleton of the drug is encapsulated within the hydrophobic cavity of II-2. As a 
result of the shielding effects of the cavity, the axial steroidal methyl protons of 
rocuronium undergo a dramatic upfield shift in their 
1
H NMR resonance. The 
signals for the methyl proton of bound rocuronium are detected at 0.23 and -0.32 
ppm. Fortunately, none of the other compounds excreted in the urine of Sprague-
Dawley rats had signals which could be observed at less than 0.8 ppm. By using a 
suitable internal standard (2,2,3,3-d(4)-3-(trimethylsilyl)propanoic acid sodium 
salt) of known concentration which also has 
1
H NMR signal in this upfield and 










H NMR spectra (600 MHz, RT, 20 mM NaH2PO4 buffered D2O, 
pH = 7.4) of: a) free rocuronium (2 mM) shows two resonances (a and b) for the 
steroidal methyl groups, b) an equimolar mixture of II-2 and rocuronium (2 
mM), a’ and b’ are resonances for steroidal methyl groups rocuronium bound in 
the II-2•rocuronium complex, and c) urine sample from a rat taken 1 h after 
reversal of rocuronium (3.5 mg kg
-1
) with II-2 (10 mg kg
-1
), a’ and b’ are 
resonances for steroidal methyl groups rocuronium bound in the II-2•rocuronium 
complex. 
 
From the urine samples of rats injected with 3.5 mg kg
-1
 of rocuronium, 
0.1 mL aliquots were withdrawn and evaporated under high vacuum.  The 
residue was dissolved in a solution containing a known concentration of 2,2,3,3-







and the sample was diluted to a total volume of 0.6 mL with 20 mM phosphate 
buffered D2O (pH = 7.4). The concentration of the II-2•rocuronium complex was 
determined by 
1
H NMR spectroscopy (Figure II-13) by comparing the integral 
for diagnostic peaks of the complex (methyl groups at 0.23 ppm and -0.32 ppm, 
3H each) relative to the internal standard (-0.02 ppm, 9H).   
Concentrations of free II-2 and rocuronium were measured by adding a 
two-fold molar excess of rocuronium or II-2 respectively to the above mentioned 
solution. Addition of excess II-2 bound any free rocuronium as the II-
2•rocuronium complex, whereas addition of excess rocuronium bound any free 
II-2 which allowed the determination of free II-2 and free rocuronium in the 
original sample by using the mass balance expressions. When administered in 
low dosage (5 to 10 mg kg
-1
), 62 ± 17 % (mean ± SD) of II-2 was detected in 
urine. The excretion of rocuronium was proportionate to the equivalents of II-2 
administered. For samples Rocuronium1 - Rocuronium4 (Table II-2), 3.5 mg kg
-1
 
rocuronium was reversed with 5 mg kg
-1
 (0.5 equivalents) of II-2. This resulted 
in the excretion of 56 ± 8 % of rocuronium in the form of the II-2•rocuronium 
complex. Whereas for samples Rocuronium5 - Rocuronium8, 3.5 mg kg
-1
 
rocuronium was reversed with 10 mg kg
-1
 (1.0 equivalent) of II-2. This resulted 
in a higher percentage of rocuronium excreted- 73 ± 21 % in the form of the II-
2•rocuronium complex. Rocuronium was eliminated in the form of the II-
2•rocuronium complex due to the high Ka of the II-2•rocuronium complex ((3.4 















H NMR Based Assay for Quantification of II-2 for 
Cisatracurium Reversal Samples. 
For the samples of rats injected with 0.6 mg kg
-1
 of cisatracurium, it was 
only possible to measure the total concentration of II-2 eliminated because we 
could not detect any diagnostic resonances for bound or free cisatracurium. The 
degradation of cisatracurium via Hoffmann elimination under physiological 
conditions further complicates the analysis (see Appendix 1). 
Table II-2. Excretion of II-2, NMBA, II-2•NMBA complex measured by 
1
H 
NMR assay for rats injected with 3.5 mg kg
-1
  rocuronium or 0.6 mg kg
-1
 
cisatracurium (values for cisatracurium and II-2•cisatracurium complex excreted 


































Rocuronium1 5, 0.5 3.5 0.87 51.4 0.77 51.4 51.4 
Rocuronium2 5, 0.5 3.5 0.85 46.6 0.67 46.6 46.6 
Rocuronium3 5, 0.5 3.5 1.4 54.6 0.83 59.9 45.5 
Rocuronium4 5, 0.5 3.5 1.08 69.2 0.96 66 53.8 
Rocuronium5 10, 1.0 3.5 1.69 37.5 1.00 56.3 37.5 
Rocuronium6 10, 1.0 3.5 0.52 87.4 2.30 87.4 87.4 
Rocuronium7 10, 1.0 3.5 0.69 76.6 2.04 76.6 76.6 
Rocuronium8 10, 1.0 3.5 0.68 90.4 2.41 90.4 90.4 
Cisatracurium1 40, 32 0.6 1.32 100 10.91 n.m.
* 
n.m. 
Cisatracurium2 60, 48 0.6 0.64 34.2 5.42 n.m. n.m. 
Cisatracurium3 60, 48 0.6 0.71 10.7 1.68 n.m. n.m. 
Cisatracurium4 60, 48 0.6 0.75 76.9 13.80 n.m. n.m. 
Cisatracurium5 80, 64 0.6 0.87 27.6 5.65 n.m. n.m. 
Cisatracurium6 80, 64 0.6 0.69 60.5 13.31 n.m. n.m. 
Cisatracurium7 80, 64 0.6 0.94 35.5 8.14 n.m. n.m. 







The total amounts of II-2 eliminated in the samples from rats treated with 
cisatracurium were obtained using the analytical technique described in section 
2.2.1 This assay relies on the addition of an excess of rocuronium to form a tight 
II-2•rocuronium complex which displays diagnostic resonances in the 
1
H NMR 
spectrum (Figure II-13). When administered in moderate doses (40 to 80 mg kg
-1
), 
49 ± 31% (mean ± SD) of the II-2 was detected in the urine samples. The results 
are summarised in Table II-2. 
2.3.3 Summary. 
In summary, we designed a 
1
H NMR based assay for the quantification of 
II-2 eliminated in the urine of Sprague-Dawley rats, taking advantage of the 
diagnostic steroidal methyl peaks of rocuronium which shift dramatically upfield 
when bound in the cavity of II-2. We used this property to measure the amount 
II-2 excreted when administered at low doses (5-10 mg kg
-1
) for the reversal of 
rocuronium as 62 ± 17%. We were also able to measure the amounts of free and 
bound rocuronium excreted by this assay and found that most of the rocuronium 
is excreted as its complex with II-2. When 0.5 equivalent of II-2 is used to 
reverse rocuronium, 56 ± 8 % of rocuronium is excreted and when 1.0 equivalent 
of II-2 is used for the reversal of rocuronium 73 ± 21 % of rocuronium is 
excreted. For samples in which cisatracurium was reversed with moderate 
dosages of II-2 (40-80 mg kg
-1











 In conclusion, we have established that II-2 displays good to high levels 
of selectivity toward the NMBAs rocuronium, vecuronium, and cisatracurium 
both in vitro and in simulations designed to capture the essence of the biological 
system.  The studies serve as a guide that allows us to prioritize the investigation 
of the efficacy of II-2 as a reversal agent for neuromuscular block when other 
drugs (e.g. II-3 – II-29) have already been or need to be subsequently 
administered.   
 By studying the excretion profile of II-2 after NMBA reversal in Sprague-
Dawley rats, we have established that more than 50% of II-2 (and rocuronium) is 
eliminated intact by the kidney within 1 hour of reversal administration.   
 Taken together, the results of the selectivity studies and pharmacodynamic 
studies serve to establish the high potential for the further development of 
Calabadion 2 (II-2) as a broad spectrum reversal agent for both amino-steroidal as 












Chapter 3: Molecular Containers as Reversal Agents for 
Drugs of Abuse  
The work presented in this chapter was taken from Ganapati, S.; Grabitz, S. D.; 
Murkli, S.; Scheffenbichler, F.; Rudolph, M. I.; Zavalij, P. Y.; Eikermann, M.; 
Isaacs, L., Molecular Containers Bind Drugs of Abuse in Vitro and Reverse the 
Hyperlocomotive Effect of Methamphetamine in Rats. Chembiochem 2017, In 
press: http://dx.doi.org/10.1002/cbic.201700289. All experiments discussed in 
this chapter were carried out by me except the in vivo studies presented in section 
3.2.5, which were carried out by Professor Eikermann and his students.  
3.1 Introduction.  
The recreational use and abuse of illicit drugs is a major societal and 
healthcare issue worldwide.
66
The cost of emergency department visits due to drug 
overdose runs into billions of dollars per annum.
68
Many patients do not survive 
drug-overdose.  
Current treatment strategies in the clinic include pharmacodynamic (PD) 
approaches for opioid overdose using drugs such as naloxone and naltrexone 
which block the effect of opioids at their biological receptors.
69
 For non-opioid 
drugs such as cocaine and methamphetamine, the clinical treatment strategies 
involve treating the adverse effects of overdose (such as elevated heart rate, 
hyperthermia, psychosis, etc.) rather than disrupting the effect of the drug itself.
71
 
Research efforts have been underway to develop pharmacokinetic (PK) strategies 
such as immunotherapeutics
81
 and enzyme based therapeutics
74







lower the concentration of the illicit drug at its receptors and thus prevent or 
reverse its biological effects. The key advantage of the PK approach over the PD 
approach is that it does not require a detailed understanding of the interaction of 
the drug with its biological receptor(s).  
The PK strategy has also been implemented using synthetic molecular 
container compounds to directly compete with biological molecular recognition 
events. For example, Sugammadex which is a γ-cyclodextrin derivative that is 
marketed worldwide by Merck under the trade name Bridion
TM
 acts as a reversal 




In the studies reported in this chapter we have investigated the potential 
use of different classes of molecular containers such as cyclodextrins, CB[n], and 
calixarenes as reversal agents for opioid and non-opioid drugs of abuse. We 
started by investigating which class of molecular hosts would serve as good lead 
compounds for structural optimization for this application, based on the in vitro 
binding affinity measurements (section 3.2). This was followed by in vivo studies 
of methamphetamine reversal by molecular host III-2 guided by the in vitro 
binding data (section 3.2.5), and finally pharmacokinetic studies for the renal 







3.2 Molecular Containers Bind Drugs of Abuse in Vitro and Reverse the 
Hyperlocomotive Effect of Methamphetamine in Rats.  
 We chose to screen the affinity of the five molecular containers 
(Calabadion 1 and 2, CB[7], III-4, and HP-β-CD) toward a panel of drugs of 
abuse (III-6 – III-12) in order to inform and prioritize subsequent in vivo work. 
The molecular containers used in this study were selected for several reasons. 
First, all of these classes of containers are known to bind to hydrophobic cations 
(e.g. for sensing, drug delivery, and reversal applications)
54 ,96 
which is a common 
structural element in drugs III-6 – III-12. Second, these molecular containers 
possess good levels of aqueous solubility (≥ 10 mM) which is required for 
efficient formulation. Third, all of these containers are easily synthesized on large 
scale by efficient procedures which make them viable scaffolds for further 
medicinal chemical optimization.  
Figure III-1. Chemical structures of: a) molecular containers, and b) drugs of 








Finally, all of these containers display good biocompatibility (in vitro and 
in vivo) and one (HP-β-CD) has even been used to formulate drugs administered 





molecular structures of the five containers will result in different binding modes 
and types of interactions (ion-dipole, ion-ion, hydrophobic, π−π, etc.) between 
container and drug; an important goal of our study was to determine which class 
of molecular containers serves as the best lead scaffold for further medicinal 
chemistry optimization in the future. In particular, the use of molecular containers 
to treat intoxication with drugs of abuse – as opposed to addiction where long 
circulation times would be needed – seems most promising. The drug panel 
includes stimulants (III-6, III-8), hallucinogens (III-9, III-10), and prescription-
type psychotherapeutics used for pain relief (III-7, III-11, III-12). All these drugs 
contain the amino functional group which is protonated at physiological pH.  
3.2.1 Qualitative Binding Study of Containers III-1 – III-5 toward 
Drugs  of Abuse by 
1
H NMR Spectroscopy.  
For containers III-1 – III-4 whose cavity constitutes an NMR shielding 
region we typically observe upfield shifts in the 
1
H NMR resonances of included 
drugs III-6 – III-12, although the kinetics of exchange is generally fast on the 
chemical shift timescale (Appendix 2) for III-1 – III-4. For example, Figure III-
1a-d shows the 
1
H NMR spectra recorded for methamphetamine (III-6), 










H NMR resonances for the aromatic ring of III-6 (He – Hg) shift 
significantly upfield within III-1•III-6 (Figure III-1c) and appear as sharp 
resonances at 1:1 stoichiometry. When 2 equivalents of III-6 are present (Figure 
III-1d) the resonances for He – Hg shift back toward the chemical shifts the 
resonances for He – Hg shift back toward the chemical shifts for free III-6 due to 





H NMR spectra recorded (400 MHz, RT, 20 mM sodium 
phosphate buffered D2O, pH 7.4) for: a) III-6 (2 mM), b) III-1 (1 mM), c) a 
mixture of III-6 (1 mM) and III-1 (1 mM), and d) a mixture of III-6 (2 mM) and 
III-1 (1 mM). 
 
The resonances for the aromatic wall of III-1 (Hu) appear as a pair of 







diastereotopic (u, u’) in the complex. For HP-β-CD, 
1
H NMR was not a useful 
analytical tool because only very minor changes in guest chemical shift are 
typically observed upon HP-β-CD•guest binding. 
 3.2.2 Stoichiometry and X-ray Crystal Structures of the 
Drug•Container Complexes. 
 The 1:1 nature of the various host•guest complexes was established by 
either Job plots (Appendix 2), x-ray crystallography, 
1
H NMR, isothermal 
titration calorimetry (ITC), or literature precedent. We were fortunate to obtain 
single crystals of CB[7]•III-6 and III-1•III-6 that were suitable for structure 
determination by x-ray crystallography.
[17]X 
Figure III-2 shows stereoscopic 
representations of individual structures of the CB[7]•III-6 and III-1•III-6 
complexes in the crystal.  
In accord with the NMR studies, the aromatic ring of III-6 is bound within 
the cavity of III-1 featuring π−π stacking (Figure III-2a). The ammonium ion is 
H-bonded to one of the ureidyl C=O groups (H•••O=C, 2.093 Å; N-H•••O angle, 
140.0°) and also benefits from ion-dipole interactions with the carbonyl portal. 
The C-shaped backbone of III-1 undergoes a helical distortion within the III-











Figure III-3.  Cross-eyed stereoviews of individual complexes of: a) 1•6, and b) 
CB[7]•6 in the crystal.  Color code: C, grey; H, white; N, blue; O, red; S, yellow; 
H-bond, red-yellow striped. 
The crystal structure of CB[7]•III-6 (Figure III-2b) also shows a deep 
penetration of the aromatic ring of III-6 into the cavity of CB[7] along with ion-
dipole and H-bonding interactions at the ureidyl C=O portal. Interestingly, four 
CB[7]•methamphetamine complexes pack into a square in the crystal driven by 
interactions between the C-H groups on the convex face of CB[7] and the C=O 
portal on an adjacent CB[7]. 
 3.2.3 Measurement of Kas between Containers III-1 – III-5 and Drugs 
of Abuse III-6 – III-12. 
 After having qualitatively investigated the binding between III-1 – III-5 
and III-6 – III-12 by 
1







CB[7] and III-1 by x-ray crystallography we set out to measure the Ka values of 
the various complexes initially using NMR and UV/Vis methods and later 
incorporating isothermal titration calorimetry (ITC) when this instrument became 
available to us in the later stages of our study. For this purpose, we employed 
various binding assays as appropriate. For example, for the weaker complexes (Ka 
< 5000 M
-1
) formed between hosts III-3 and III-4 whose cavities constitute NMR 
shielding regions and drugs III-6 and III-8 – III-11 we used direct 
1
H NMR 
titrations of guest with host and fitted the change in chemical shift to a standard 
1:1 binding model (Table III-1, Appendix 2). Based on our extensive experience 
measuring CB[n]•guest binding constants, we chose a 
1
H NMR competition 
assay
18,90,20




 for CB[7]•methamphetamine. For 
stronger complexes involving III-1 and III-2 we employed UV/Vis competition 
assays developed by us previously.
39 
For this purpose, we form the III-
1•rhodamine 6G or III-2•rhodamine 6G complexes which show different UV/Vis 
spectra than free rhodamine 6G and then titrate those complexes with drug which 
induces the reverse UV/Vis change. Based on a knowledge of the total 
concentrations of container, rhodamine 6G and the III-1•rhodamine 6G and III-
2•rhodamine 6G binding constants we fitted the change in UV/Vis absorbance 
versus [drug] to a competition binding model
39 
to extract the unknown 
container•drug complex Ka value (Table III-1). For example, Figure III-3a shows 
the UV/Vis spectra recorded when a solution of III-2 (4.97 μM) and rhodamine 







whereas Figure III-3b shows the fitting of the data to the competition binding 




 for III-2•methamphetamine. 
 
 
Figure III-4. a) UV/Vis spectra recorded during the titration of a mixture of III-2 
(4.97 μM) and rhodamine 6G (4.97 μM) with methamphetamine (6, 0 – 219 μM) 
in 20 mM NaH2PO4 buffered water (pH 7.4). b) Plot of absorbance versus [2] 




. c) ITC 
thermogram recorded during the titration of III-2 (87 μM) in the cell with 
hydromorphone (0.93 mM) in the syringe. d) Fitting of the data to a 1:1 binding 





The remaining complexes – mainly HP-β-CD•drug but also 
container•fentanyl and container•hydromorphone – were measured by ITC when 
the instrumentation became available in the lab (Table III-1, Appendix 2). For 
example, Figure III-3c,d shows the thermogram recorded for the titration of III-2 
(87 μM) with hydromorphone III-12 (0 – 200 μM) which was fitted with the 





ΔH = -2.1 ± 0.3 kcal mol
-1 










Table III-1. Binding constants (Ka, M
-1
) determined for the various 
container•drug complexes. 
Guest  III-1 III-2 III-3 III-4 III-5  
III-6  (7.5 ± 2.9) × 10
6 a) (4.3 ± 1.0) × 106 a) 1.2 × 108 c) (3.8 ± 0.6) × 104 b) (1.9 ± 0.3) × 102 d) 
III-7  (1.1 ± 0.04) × 10
7 d) (7.6 ± 0.5) × 106 d) (1.8 ± 0.1) × 107d) (1.1 ± 0.1) × 104 d) (3.0 ± 0.5) × 103 d) 
III-8 (6.6 ± 0.4) × 10
5 a) (1.0 ± 0.1) × 106 a) (2.3 ± 0.2) × 103 b) (4.3 ± 1.5) × 104 b) (1.7 ± 0.3) × 102 d) 
III-9 (1.1 ± 0.1) × 10
4 a),e) (2.1 ± 0.1) ×105 a),e) (6.4 ± 1.2) ×102 b) (2.0 ± 0.2) × 104 d) (1.1 ± 0.2) × 102 d) 
III-10 (4.7 ± 0.5) × 10
4 a) (2.1 ± 0.1) × 105 a) (4.4 ± 0.9) × 103 b) (4.5 ± 0.3) × 104 d) (1.0 ± 0.03) × 103 d) 
III-11 (5.3 ± 0.3) × 10
5 a) (5.3 ± 0.4) × 105 a),f) n.b. (4.9 ± 0.3) × 104 b) n.b. 
III-12 (1.8 ± 0.03) × 10
5 d) (6.8 ± 0.1) × 105 d) n.b. (1.0 ± 0.04) × 104 d) (2.8 ± 0.5) x 102 d) 
a) Measured by UV/Vis competition assay. b) Measured by direct 
1
H NMR 
titration. c) Measured by 
1
H NMR competition assay. d) Measured by ITC. n.b. – 





The other ITC derived thermodynamic parameters given in Table III-1 
were carried out analogously. Previously, we have shown that the results of 
UV/Vis competition assays and direct ITC titrations involving Calabadions 1 and 
2 and guests give comparable values which gives us confidence in comparisons 
between Ka values measured by the different techniques.
97
 
3.2.4 Commentary on the Tabulated Ka Values.   
 An examination of the Ka values given in Table III-1 reveals that they 




. HP-β-CD, which is 
well known as a promiscuous and low affinity host, unsurprisingly displays 











between neutral HP-β-CD and cationic drugs as well as the absence of typical 
high affinity binding epitopes (e.g. adamantyl residue) on the drugs is presumably 
responsible for the weaker binding. In contrast, the tetraanionic calix[4]arene 
derivative III-4 displays larger Ka values but they cluster in the narrow range of 
1.0 x 10
4




. The lack of selectivity in this case may be due to the 
relative importance of the electrostatic contributions to the binding free energy. 
Most interesting, and encouraging as lead compounds for the further development 
of reversal agents for in vivo intoxication with drugs of abuse, are the three 
CB[n]-type molecular containers Calabadion 1 and 2 and CB[7]. These three 







 range. Given the presence of phenethylammonium binding epitopes it is not 









). Furthermore, CB[7] 
discriminates against the more sterically encumbered drugs (Ka < 4400 M
-1
) due 
to unfavorable steric interactions in the CB[7]•guest complexes. In contrast, the 
acyclic CB[n]-type containers Calabadion 1 and Calabadion 2 have a more 
flexible cavity which can flex to accommodate a range of guest sizes and display 






) and some selectivity toward 
the panel of drugs of abuse. The complexes between the tetraanionic Calabadions 
and cationic drugs benefit from electrostatic interactions and π−π interactions 
between guest aromatic rings and host aromatic walls. Similar to CB[7], 
Calabadion 1 and Calabadion 2 display highest affinity toward methamphetamine 













2 and CB[7], CB[7] displays the highest levels of affinity and selectivity toward 
the drugs of abuse panel. However, the affinity and selectivity of III-1 and III-2 
seen herein and also documented in the context of neuromuscular block reversal,
97 
is substantial and suggests that III-1 and III-2 could serve as core scaffolds for 
further structural optimization. We are mindful of the fact that metabolites of 
amino acids, especially phenylalanine, will likely display similar binding affinity 
toward Calabadion 2 as methamphetamine does which could compromise in vivo 
efficacy. Accordingly, and given the fact that Calabadion•guest complexes are 
eliminated in the urine over several hours,
63,64 
we do not envision the use of 
Calabadion 2 for long term treatment of methamphetamine addiction. However, 
such consideration of circulation time and discrimination against related 
metabolites are less relevant in the context of treatment of drug overdose and 
intoxication where dose can simply be adjusted to prevent mortality. 
3.2.5 In Vivo Reversal of Methamphetamine by Calabadion 2. 
  Accordingly, we decided to test the ability of an acyclic CB[n]-type 
receptor and unfunctionalized CB[7] as an in vivo reversal agent for 
methamphetamine intoxication. We choose Calabadion 2 as the acyclic CB[n] test 
compound because of its documented high biocompatibility (e.g. low in vitro 
cytotoxicity, high in vivo maximum tolerated dose, passed Ames test, no hERG 
ion channel inhibition)
95 
and because of its generally higher binding affinity 
toward its guests.
48,44 
With the help of our collaborators Eikermann and co-







Calabadion 2 and CB[7] toward methamphetamine could prevent or reverse its in 
vivo biological effects. For this assay, Eikermann and co-workers took advantage 
of the known increase of locomotor activity (e.g. movement) of rats upon 
treatment with methamphetamine.
98 
A total of 21 male Sprague-Dawley rats 
(weight, mean ± SD: 288 ± 14 g) were tested repeatedly in a randomized 
controlled crossover setting. A single bolus of methamphetamine (0.3 mg kg
-1
) or 
placebo was injected intravenously via a tail vein catheter to assess baseline 
locomotor activity. Two types of studies were performed. In the treatment studies, 
Calabadion 2 (65 or 130 mg kg
-1
) or CB[7] (45 or 90 mg kg
-1
) was administered 
30 seconds after methamphetamine whereas in the prevention studies, rats were 
pretreated with Calabadion 2 (Figure III-5) 30 seconds before methamphetamine 
treatment via tail vein catheter. The catheter was flushed with 1 mL normal saline 
in between injections to ensure that methamphetamine was not simply complexed 
by Calabadion 2 inside the catheter. The animals were placed in the center of a 
100 x 100 x 40 cm open field and their locomotor activity was video recorded for 
20 minutes. The location of the rat and the total distance traveled was analyzed 
using the ANYmaze (version 4.5, Stoelting, Wood Dale, IL, USA) software. 
Values are given in percent of the placebo + methamphetamine activity level and 
reported as mean ± standard error of the mean. As expected, the rats only treated 
with placebo in addition to methamphetamine exhibit enhanced levels of 
locomotor activity relative to their baseline: (n = 21; 26.5 ± 4.9) m vs. (5.8 ± 1.5) 
m; p<0.001. Encouragingly, the preventive use of Calabadion 2 (65 or 130 mg kg-







(74.4 ± 3.8)% (p<0.001), respectively, compared to placebo + methamphetamine 
(Figure III-5a).  
 
Figure III-5. Results from behavioral tests in the open field. a) Bar graph 
showing distance traveled in percent of the placebo + methamphetamine activity 
level within 20 minutes; error bars represent the standard error of the mean. 
*p<0.01 compared to methamphetamine + placebo. **p<0.001 compared to 
methamphetamine + placebo. #interaction term indication × Calabadion 2 dose: 
p<0.001, indicating effect modification by time of administration of Calabadion 2. 
Tracking plots illustrating the traveled distance of one rat within 20 minutes in the 
open field: b) Baseline, no methamphetamine given, c) following 
methamphetamine (0.3 mg kg
-1
) + placebo, d) following methamphetamine (0.3 
mg kg 
-1
) + Calabadion 2 (65 mg kg
-1
), and e) following methamphetamine (0.3 
mg kg
-1









Similarly, the treatment study with Calabadion 2 (130 mg kg
-1
) 
significantly decreased the traveled distance by (43.8 ± 11.2)% compared to 
placebo + methamphetamine (p=0.004), whereas no significant reduction of 
methamphetamine induced hyperlocomotion was observed when treated with 65 
mg kg-1 of 2 (p=0.625). As a control, it was determined that a bolus of 
Calabadion 2 alone (130 mg kg
-1
) without methamphetamine did not affect the 
locomotion compared to baseline (33.5 ± 17.7% vs. 32.9 ± 15.0%; p = 0.982). A 
smaller dose of Calabadion 2 was required in a prevention setting compared to a 
treatment setting to reverse methamphetamine-induced hyperlocomotion 
(interaction effect of indication × Calabadion 2 dose for locomotor activity: 
p<0.001), indicating effect modification. In our previous studies of the use of 
Calabadion 1 and 2 to reverse neuromuscular block, we found that the majority of 
the drug was eliminated in the urine of the rats as the non-metabolized 
Calabadion•drug complex within two hours.
63,64,95  
We posit that Calabadion 2 functions in a similar way to modulate the 
hyperlocomotive effect induced by methamphetamine described herein. The 
substantially higher doses of Calabadion 2 required for methamphetamine 
reversal than for neuromuscular block reversal likely reflects the tighter binding 
of methamphetamine to its biological targets and/or kinetic issues of intravenous 
sequestration of methamphetamine once it has crossed the blood-brain barrier. We 
expect that the Calabadion framework will enable a medicinal chemistry 







contrast, treatment with CB[7] (45 mg kg
-1
 or 90 mg kg
-1
) did not affect the 
distance traveled compared to placebo + methamphetamine: (87.0 ± 42.6)%, 
p=0.773 and (119.5 ± 55.4)%, p=0.739, respectively). As a control, it was verified 
that injection of CB[7] alone had no significant effect on locomotion compared to 
baseline (19.3 ± 6.0% vs. 21.6 ± 6.9%; p =0.546). 
 3.2.6 Summary. 
In summary, we have screened the binding affinity of molecular 
containers III-1 – III-5 toward seven drugs of abuse by a combination of direct 
and competitive 
1
H NMR, UV/Vis, and ITC binding assays. The structures of the 
III-1•methamphetamine and CB[7]•methamphetamine complexes were solved by 
single crystal x-ray diffraction. Calabadion 1 and Calabadion 2, in particular, 
display very good levels of affinity across the full range of drugs and display 
highest affinity toward methamphetamine and fentanyl. We find that the 
hyperlocomotive activity of rats given methamphetamine could be both prevented 
and treated by Calabadion 2 (65 or 130 mg kg
-1
). The documented 
biocompatibility of the Calabadions
40,95,99
 and their convergent building block 
synthesis
44 
suggest fruitful pathways toward their further structural optimization 
for development as reversal agents for intoxication with non-opioid drugs of 







3.3 Renal Elimination of Calabadion 1 and Fentanyl in Rats Post Reversal 
Application.   
 In order to gain insight into the in vivo reversal capability and 
pharmacokinetic profiles of the drugs of abuse and Calabadion type reversal 
agents studied in section 3.2, our collaborator Professor Eikermann and co-
workers are performing in vivo reversal studies for the most promising drug 
container•complexes using the Kas in Table III-1 as a guide.
100
 Fentanyl (III-7) is 
a potent surgical anesthetic as well as a recreationally abused opioid drug.
76 
The 




and is one of the tightest 
complexes determined in this work.
100
 Accordingly, the Eikermann group treated 




 over 15 minutes), followed by a bolus dose of placebo (saline) or test 
reversal agent (III-1, 50 mg kg
-1
). One hour after placebo or reversal agent 
administration, bladder surgeries were performed; the urine was collected, and 
subsequently was analyzed by us. The quantification of III-7 was achieved with 
an HPLC based assay
99





 3.3.1 Fentanyl Calibration Curve. 
 The dosage of III-7 used for the two rat groups was too low (12.5 μg kg
-1
) 
to be detected by 
1
H NMR. Therefore a more sensitive HPLC based assay for 
measuring the μM concentrations of III-7 in the urine was designed. Based on the 
literature precedent for the pharmacokinetics of  intravenously administered III-7 
in rat muscle and plasma
101







of III-7 being eliminated in urine, 102 we estimated that about 24-34 % of III-7 
should be excreted unmetabolized. We modified an assay previously published by 
the Isaacs group for the detection of albendazole and its metabolites in mouse 
plasma by HPLC
99 
to obtain a calibration curve for fentanyl. 
 
Figure III-6. HPLC spectrum of a standard solution of III-7 (14 μM) showing a 
retention time of 13.8 minutes for III-7 at 229 nm. The peak at 2.7 minutes is 
from trimethylamine in the buffer.   
 
   For this purpose, a 13.13 mM stock solution of III-7 was prepared by 
dissolving 11.8 mg III-7 in 1.7 mL HPLC grade water. This stock solution was 
diluted, evaporated, and reconstituted in the HPLC mobile phase (1.3% v/v 
trimethylamine in 60% water, 27% methanol, 13% acetonitrile) to obtain 
solutions with a concentration range of 5.7 μM – 19 μM. These solutions were 
injected (20 μl injection volume) onto a Microsorb-MV 100-5 C18 column (5 μm, 
250 × 4.6 mm) and the area under the peak at 13 – 14 min. was plotted against the 
gravimetric concentrations to obtain a linear calibration curve (R
2 









Figure III-7. Calibration curve for fentanyl using working standard solutions.  
 
 3.3.2 Fentanyl Excreted by Rats Injected with Fentanyl and Placebo. 
 For the urine samples of rats injected with fentanyl and placebo (saline), 
we expected about 24-34 % of III-7 to be excreted. Accordingly, the samples 
with Rat I.D. 1, 2, 3, 7, 8, and 9 were analyzed by HPLC.  A measured volume of 
urine sample from these rats was evaporated under high vacuum. These samples 
were reconstituted in a smaller volume of mobile phase in order to make the 
concentrations of III-7 higher than the detection limit of our protocol. The 
concentrated samples were injected (20 μL) and the fentanyl peak was observed at 
14 - 15 minutes. Since the retention time for fentanyl fluctuated by ± 1 minute 
between samples, and there were other peaks from substances present in the urine 
sample adjacent to the fentanyl peak, we needed to confirm the identity of the 
fentanyl peak. For this purpose, we ran each sample two times. First we obtained 
a spectrum of the original sample, followed by injecting the same sample spiked 
with a 2-fold excess of fentanyl. Based on comparing the retention time and 
position of the peak whose area increased by 2–fold in the second run to the 
y = 2.55x 
























corresponding peak in the first run, we were able to confidently identify the 
fentanyl peak in the first run and distinguish it from the other substances present 
in the urine sample. The area of this fentanyl peak was used to calculate the 
corresponding gravimetric concentration of fentanyl using the calibration curve in 
Figure III-7. 
 
Figure III-8. HPLC spectra of: a) blank urine spiked with fentanyl, and b) one of 
the representative urine sample following the fentanyl injection to rat. The 
fentanyl peak can be seen at 14.4 and 14.3 minutes respectively. 
 
The concentration of III-7 in urine and the urine volume were used to calculate 
the weight and the weight percentage of III-7 excreted. The average percent 
excretion of III-7 in rats injected with III-7 + placebo was (17 ± 9) %, the results 







Table III-2.  Excretion of III-7 and III-1 measured by HPLC and 
1
H NMR 
assays for rats injected with 12.5 μg kg
-1




 infusion over 
15 minutes) and placebo or 50 mg kg
-1



























         
1 0.357 4.46 0 0.344 0.225 5.1 - - 
2 0.342 4.27 0 0.470 0.199 4.7 - - 
3 0.361 4.15 0 0.527 0.759 18.3 - - 
7 0.303 3.79 0 0.657 1.090 28.8 - - 
8 0.301 3.76 0 1.080 0.764 20.3 - - 
9 0.284 3.55 0 0.860 0.875 24.7 - - 
4 0.380 4.75 19.00 0.860 0.914 19.2 4.317 22.7 
5 0.360 4.50 18.00 0.890 1.135 25.2 7.127 39.6 
6 0.342 4.27 17.10 1.250 1.238 29.0 7.049 41.2 
10 0.301 3.76 15.05 0.900 0.905 24.1 7.405 49.2 
11 0.304 3.80 15.20 0.505 0.553 14.5 6.978 45.9 
12 0.307 3.84 15.35 0.915 1.224 31.9 6.000 39.1 
 
 
3.3.3 Fentanyl Excreted by Rats Injected with Fentanyl and 
Calabadion 1. 
 The second group of rats were injected with III-7 followed by reversal 
with III-1. For these samples we designed a protocol to first separate the excreted 
III-7 from its III-1 complex so that we could quantify the drug and reversal agent 
separately. For this purpose, a known volume of urine from Rat I.D. 4, 5, 6, 10, 
11, and 12 (500 μL) was evaporated under high vacuum. Each sample was mixed 
with 2 mL methanol, sonicated and vortexed in order to extract III-7 into solution 







centrifuged to separate the supernatant from the precipitate. The supernatant 
methanol solutions were dried under high vacuum and reconstituted in 125 μL of 
mobile phase and injected into the HPLC system and quantified as described in 
section 3.3.2. The average percentage excretion of III-7 in these samples was 
found to be (24 ± 6) %. The results are summarized in Table III-2. 
 3.3.4 Calabadion 1 Excreted by Rats Injected with Fentanyl and    
          Calabadion 1. 
 The urine samples from rats injected with III-1 as reversal agent (Rat I.D. 
4, 5, 6, 10, 11, and 12) were analysed for the quantification of III-7 by the HPLC 
assay described in section 3.3.3. Since the dosage of III-1 in these samples was 
high enough (50 m kg
-1
) to obtain mM quantities in urine,
63
 we designed a 
1
H 
NMR based assay to quantify compound III-1. The precipitate obtained from 
methanol in the previous step (section 3.3.3) was dried and reconstituted in 2 mL 
deuterium oxide, and centrifuged. The concentration of compound III-1 in this 
solution was measured by 
1
H NMR by comparing the peak area of the methyl 
protons of III-1 at 1.8, 1.76 ppm with the methyl protons of a known 
concentration 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TMSP) 
internal standard at -0.05 ppm (Figure III-9). TMSP was chosen as the internal 
standard because it is a negatively charged molecule which does not bind to III-1, 
resulting in a single sharp peak at -0.005 ppm corresponding to 9 methyl 
protons.
64
 Additionally the position of its resonance in 
1
H NMR appears very 
upfield (at -0.05 ppm) in a region uncluttered by any other peaks from III-1 or 











H-NMR spectrum of a representative urine sample following the 
injection of III-7 and III-1 to a rat (600 MHz, D2O). 
 
This separation of peaks in 
1
H NMR allows us to obtain reliable peak 
integrals which are correlated to its known concentration in the solution. We were 
fortunate that the methyl protons of III-1 (at 1.80 ppm and 1.76 ppm, 
corresponding to 12 protons) were also free from overlap from other signals in the 
1
H NMR spectrum and could be integrated reliably. Integrals of the methyl peaks 
of III-1 and TMSP were obtained by line shape fitting using the Gaussian model 
in TopSpin
TM
 software. We also adjusted the acquisition parameters for collecting 
the 
1
H NMR data, such that a long delay time (D1) of 74 s was chosen so that it 







ensured that TMSP was fully relaxed between successive scans, and III-1 was 
also expected to be fully relaxed since larger molecules have shorted relaxation 
times. The concertation of III-1 calculated in urine and urine volume were used to 
calculate the weight percentage of III-1 excreted as (40 ± 8) %. 
 3.3.5 Summary. 
 The reversal of fentanyl was effected in Sprague-Dawley rats using 
molecular container III-1. The renal elimination of III-7 was analyzed by an 
HPLC assay for comparison between rats injected with placebo (saline) vs rats 
injected with reversal agent III-1. In case of placebo administration, (17 ± 9) % of 
III-7 was eliminated and in case of reversal by III-1, (24 ± 6) % of III-7 was 
eliminated in urine in 1 hour. A significant difference in renal elimination of III-7 
was not observed between the two cases taking into account the errors in 
measurement. The elimination of III-1 by the kidneys was found to be (40 ± 8) % 




 In conclusion, we have established that CB[n] based molecular containers- 
III-1, III-2, and III-3 display higher affinities than calixarene (III-4) and 
cyclodextrin (III-5) based containers toward the panel of drugs of abuse (III-6 – 
III-12) studied in this work. In particular CB[7] shows the highest selectivity for 
smaller phenethylammonium containing drugs III-6 and III-7, whereas the 
Calabadion scaffold seems to be the most suitable for binding the full range drugs 







reversal of methamphetamine by III-2 and not CB[7] further establishes the 
Calabadion scaffold as promising for further development.  By studying the 
excretion profile of III-7 and III-1 post reversal in Sprague-Dawley rats, we have 
found that on an average 24 % fentanyl and 40% Calabadion 1 are eliminated by 
the kidneys in 1 hour.  
 These results serve as encouraging preliminary data for the further 
development of molecular containers, especially CB[n] as reversal agents for 
drugs of abuse. They also point to the need for the further optimization of the 
Calabadion scaffold to develop reversal agents with higher in vitro Ka values for 
more potent in vivo efficacies for the sequestration of illicit drugs. Along with 
other PD and PK strategies being developed for the treatment of drug overdose, 
molecular containers show great promise to expand the toolbox of treatment 
options for tackling the social and healthcare issues associated with drug abuse 








Chapter 4: Synthesis and Molecular Recognition Properties 
of Acyclic Cucurbit[n]urils with Alkyl Linkers  
4.1 Introduction.  
Cucurbit[n]urils (CB[n]) are a class of molecular containers well-known 
for their high affinities, selectivities, and stimuli responsiveness towards various 
guests, especially hydrophobic diammonium cations.
18,103
 Accordingly, CB[n] 
compounds have been used in a wide range of applications, including drug 
delivery,  drug reversal, molecular machines, and sensing ensembles.
104
 In order 
to expand the scope of CB[n] applications and improve their properties such as 
aqueous solubility, functionalization approaches to obtain modified CB[n] is an 





Figure IV-1. Chemical structures of: a) cucurbit[n]urils (CB[n]) and Calabadion 








In 2012, Isaacs and co-workers reported the synthesis of an acyclic CB[n] 
Calabadion 1 (Figure IV-1 a) which contains a glycoluril tetramer backbone while 
incorporating aromatic side walls with solubilizing sulfonate groups attached via 
alkyl chains. Calabadion 1 was reported as an effective solubilizing excipient for 
poorly water soluble drugs
40
 and as a reversal agent for neuromuscular blocking 
agents (NMBAs).
48
 Subsequently, the Isaacs and Sindelar groups have reported 
many host compounds which are structurally related to IV-1. The modular 
synthesis of IV-1 and related compounds has facilitated the synthesis of 







 and length of the alkyl chain connecting the solubilizing group 
to the glycoluril backbone.
45
  The effect of these structural modifications on the 
ability of these new hosts to bind guest molecules as compared to IV-1 has also 
been previously studied. From these studies, it has been found that generally a 
larger glycoluril oligomer (e.g.: tetramer as compared to trimer, dimer, or 
monomer), larger aromatic walls (e.g.: substituted naphthalene as compared to 
substituted benzene), and negatively charged solubilizing groups (e.g.: sulfonate 
as compared to neutral or positive groups) lead to more potent molecular hosts 
with higher binding affinities towards guests such as hydrophobic diammonium 
cations. The binding affinity of IV-1 toward drugs of abuse such as fentanyl and 




) as discussed in Chapter 3, and 
renders it as a promising scaffold for further medicinal chemistry optimization for 
the purpose of developing a reversal agent for sequestering drugs of abuse.
100
 In 







linkers of varying lengths capping one side of IV-1. We have also studied their 
aqueous solubility, self-association properties and molecular recognition 
properties toward guests (IV-6 – IV-10) and compared them to those of IV-1.  
4.2 Design and Synthesis of Hosts IV-2a – IV2c.  
The synthesis of host IV-1 was previously reported by the double 
electrophilic aromatic substitution reaction of the glycoluril tetramer bis(cyclic 
ether) building block (IV-5) with the corresponding dialkoxyaromatic sidewall 
IV-4 in trifluoroacetic acid.
40
 The high binding affinity of IV-1 toward various 
hydrophobic ammonium cations has been attributed to its ureidyl carbonyl portals 
resulting from the glycoluril tetramer backbone which is preorganized into a C-
shape facilitating guest encapsulation. The cavity of IV-1 is in part defined by 
aromatic walls which facilitate π-π interactions with guests containing aromatic 
groups, further stabilizing the complex. The sulfonate arms enhance the solubility 
of host IV-1 in water and also provide favorable electrostatic interactions with 
positively charged guests. In designing congeners of IV-1 we wanted to preserve 
the carbonyl portals, aromatic walls, and sulfonate solubilizing groups to maintain 
the recognition properties and aqueous solubility of IV-1, while improving the 
preorganization of the cavity size of the acyclic host by locking the distance 
between sidewalls and providing additional binding sites to the hydrophobic parts 
of larger guest molecules which could protrude from the host cavity. 
Accordingly we hypothesized that the binding affinity of IV-1 toward 
hydrophobic cations could be increased by incorporation of a covalent capping 







of varying chain lengths (ethyl, hexyl, and decyl) with hydroquinone under basic 
conditions to obtain precursors with alkyl linkers, compounds IV-3a, IV-3b, and 
IV-3c in 13%, 50%, and 33%  yield respectively (Scheme IV-1a).
106,107
 Precursor 
IV-3 was alkylated with 1,3-propanesultone to obtain the aromatic sulfonate walls 
with alkyl linkers, IV-4a, IV-4b, and IV-4c in 87%, 77%, and 47% yield 
respectively (Scheme IV-1b).  
 
Scheme IV-1. Synthesis of hosts 2a – 2c. 
 
Compound IV-5 was refluxed with IV-4 (analogous to the synthesis of 
IV-1)
40
 in a mixture of trifluoroacetic acid and acetic anhydride, to obtain alkyl 
capped congeners of IV-1, compounds IV-2a, IV-2b, and IV-2c in 33%, 13%, 
and 26% yield respectively. Compounds IV-2a – IV2c were purified by Dowex 
ion exchange chromatography (Dowex® 1X2 chloride form, 200-400 mesh ion 







the aromatic walls as is confirmed from the 
1
H NMR splitting patterns of the 
methylene protons of the glycoluril backbone on the same and opposite sides of 
the alkyl linker (Figure IV-2b and Appendix 3).  
4.3 Solubility Properties of Hosts IV-2a – IV2c. 
 The use of molecular containers for biological applications such as drug 
reversal and drug solubilization requires their good inherent solubility in water as 
well as the aqueous solubility of their complexes with relevant guest molecules. 
The solubility of IV-1 was reported as 105 mM in 20 mM monosodium phosphate 
buffer at pD 7.4 in deuterium oxide.
40
 We used the same technique as that 
reported for IV-1 for measuring the solubility of our hosts and found that the 
solubilities of IV-2a, IV-2b, and IV 2c are 1.8 mM, 1.5 mM, and 1.7 mM 
respectively in 20 mM monosodium phosphate buffer at pD 7.4 in deuterium 
oxide. This dramatic drop in aqueous solubility by two orders of magnitude was 
unexpected, but can be attributed to the loss of two sulfonate groups per host 
while incorporating linkers into IV-2a – IV-2c. While this reduced aqueous 
solubility makes IV-2a – IV-2c less attractive for use in biological systems as 
compared to IV-1, we decided to investigate the effect of the alkyl linker on the 
self -association properties and the molecular recognition properties of these hosts 
toward some common guests for CB[n]. 
4.4 Self-Association Properties of Hosts IV-2a – IV2c. 
The self-association of IV-1 has been previously studied by dilution 
experiments monitored by 
1
H NMR spectroscopy. It was found that the observed 












 In general the Ks of acyclic CB[n] which are structurally 
related IV-1 (in that they have a glycoluril backbone and aromatic walls with 
sulfonate arms) have been reported as less than 1000 M
-1
. This low tendency to 




Fortunately our dianionic hosts IV-2a – IV-2c also showed no significant 
changes in chemical shift in 
1
H NMR dilution studies over the accessible 
concentration range (1.0 – 0.1 mM) in deuterium oxide buffered to pD 7.4. This 
low tendency for self-association is a desirable property for molecular hosts as it 
leaves their cavity accessible for guest binding.  
While the intermolecular association in IV-2a – IV2c is low, we did note 
some concentration independent intramolecular features in the 
1
H NMR spectra of 
our hosts which suggest the partial inclusion of the alkyl linker within the 
hydrophobic cavity of each host molecule. Figure IV-2b shows the 
1
H NMR 
spectrum of host IV-2b in which the resonances of the methylene protons of the 
linker Hf, He’, and He are shifted upfield by 0.5 ppm relative to their resonances in 
IV-4b (Appendix 3). This can be explained by the shielding effect of the 
hydrophobic cavity of IV-2b which stabilizes the alkyl linker of the host in water 
by the hydrophobic effect. The resonance for Hg is not significantly different 
between IV-2b and IV-4b indicating that its magnetic environment is unchanged 
and it does not enter the cavity of IV-2b. The same effect is observed for host IV-







(except the ones directly attached to the aromatic wall) are upfield shifted by 0.2 - 




H NMR spectra recorded (400 MHz, RT, 20 mM sodium 
phosphate buffered D2O, pH 7.4) for: a) IV-8 (1 mM), b) IV-2b (1 mM), c) a 
mixture of IV-8 (0.5 mM) and IV-2b (0.5 mM), and d) IV-8 (1.0 mM) and IV-2b  
(0.5 mM). 
 
Since the decyl linker is longer and has more degrees of freedom than the 
hexyl linker we observed a broadening of the 
1
H NMR signals of the protons in 







decyl linker also penetrates more deeply into the its cavity relative to the hexyl 
linker on account of its longer length, as is evidenced by the larger upfield shifts 
of its methylene protons at the mid-point of the linker. In case of host IV-2a, the 
linker is shortest (ethyl group) and the methylene groups are both directly 
attached to the aromatic walls of the host. Two well-resolved resonances are 
observed for the linker protons in IV-2a at 4.47 ppm and 3.87 ppm respectively. 
The resonance at 3.87 ppm is shifted upfield by 0.5 ppm relative its position in the 
1
H NMR spectrum of IV-4a (Appendix 3) which indicates that this set of protons 
is experiencing a different magnetic environment, potentially from the anisotropic 
effect of the aromatic walls of the host. The other set of protons whose chemical 
shift is observed at 4.47 ppm are out of the plane of the aromatic walls and 
therefore do not experience any shielding effect.   
 This phenomenon of the alkyl linker of the hosts IV-2a – IV-2c interacting 
with or being partially included within their cavities is expected to create an 
energetic penalty for guest molecules to be included within their cavities. In the 
following sections we investigate the thermodynamic costs of this phenomenon 
qualitatively and quantitatively.   
4.5 Binding Properties of Hosts IV-2a – IV-2c and IV-1 towards Guests IV-6 
– IV-10 Investigated by 
1
H NMR. 
Initially, we tried to investigate the ability of hosts IV-2a – IV-2c to bind 
typical dicationic guests known to bind to CB[n] such as 1,6-diamino hexane, 1,6-
diamino cyclohexane, and p-xylene diamine. We found that the complexes of 







from water. We rationalize this precipitation as a consequence of the formation of 
a zwitterionic host-guest complex which would have lower aqueous solubility. 
Therefore we decided instead to study the water soluble complexes of 
monocationic guests IV-6 – IV10 with hosts IV-2a – IV-2c and IV-1 by 
1
H NMR 
spectroscopy. For all these complexes we commonly observed upfield shifting of 
guest resonances which indicates that these protons on the guest are located in the 
cavity of the host molecule. The upfield shifting of guest resonances in the 
complexes with hosts containing alkyl linkers (IV-2a – IV-2c) was generally less 
than or equal to the upfield shifting of the same resonances in the complexes with 
host IV-1. This preliminary observation indicates that in most cases the cavity of 
host IV-1 better accommodates guests IV-6 – IV-10 as compared to the cavities 
of IV-2a –IV2c which are more constrained due to the presence of the alkyl 
linkers. All of the host guest complexes display fast kinetics of exchange on the 
1
H NMR timescale which suggests that these complexes would be of moderate 
stability in water. In general, the binding of guests IV-6 – IV-10 to hosts IV-2a – 
IV-2c resulted in the downfield shifting of the resonances of the linker protons of 
the host molecule indicating that guest binding displaces the linkers from within 
the cavity of the host. The 
1
H NMR spectrum of the IV-2b·IV-8 complex is 
presented in Figure IV-2 to facilitate discussion of the binding features of this 
complex. The resonances of the aromatic protons Hb, Hc, Hd of IV-8 undergo 
upfield shifting in its complex with IV-2b as a result of the anisotropic 
environment of the aromatic walls of the host when the host and guest are 







peak corresponding to Hb, Hc, and Hd protons shifts to a position which is the 
average between the free (Figure IV-2a) and bound (Figure IV-2c) forms of the 
guest. This indicates a fast kinetics of exchange between free guest IV-8 and the 
IV-2a·IV-8 complex relative to the 
1
H NMR chemical shift time scale. The same 
trend is observed for the Ha methylene protons of IV-8 in free and bound form 
which experience the shielding effect of the cavity of the host when bound to IV-
2b. The resonances of the aromatic protons of host IV-2b, Hv and Hu also undergo 
upfield shifting in the IV-2b·IV-8 complex as a result of the anisotropic effect of 
the aromatic group of IV-8. The resolution of the Hv, Hu multiplet peak of IV-2b 
(Figure IV-2b) into two sharp doublets (J =9.0) in the IV-2b·IV-8 complex 
instead of four peaks or broadening indicates the facial selectivity of the guest IV-
8 in binding to the cavity, presumably with the aromatic end of IV-8 facing the 
alkyl linker of IV-2b and the ammonium group of IV-8 facing the sulfonate 
groups of IV-2b. The other noteworthy change in the spectrum of IV-2b occurs to 
the resonances of the Hf, He’, and He protons of the linker. In the spectrum of the 
IV-2b·IV-8 complex these protons are shifted downfield by 0.5 ppm relative to 
their positions in free IV-2b, at the same positions where they were observed in 
the spectrum of IV-4b (Appendix 3). This downfield shift indicates that the 
presence of guest IV-8 in the cavity of host IV-2b necessitates the displacement 
of the hexyl linker from the cavity of IV-2b. Analogous phenomena were seen in 
the 
1








4.6 Measurement of Binding Affinities between Hosts IV-2a – IV-2c and IV-1 
and Guests IV-6 – IV-10 by Isothermal Calorimetry (ITC). 
The binding affinities (Ka) of the hosts IV-2a - IV-2c and IV-1 with 
monocationic guests IV-6 – IV-10 were measured by ITC (Table IV-1). 
 
Figure IV-3. a) ITC thermogram recorded during the titration of IV-2b (0.1 mM) 
in the cell with IV-8 (1.0 mM) in the syringe. d) Fitting of the data to a 1:1 






 For example, Figure IV-3 shows the thermogram recorded for the titration 
of IV-2b (100 μM) with IV-8 (0 – 200 μM) which was fitted with the MicroCal 











± 0.1 kcal mol
-1
 for the IV-2b•IV-8 complex. The other ITC derived 
thermodynamic parameters given in Table IV-1 were carried out analogously.  
Table IV-2. Binding constants determined by ITC for the interaction between 
molecular containers IV-1, IV-2a – IV-2c and guests IV-6 – IV-10. 
Conditions: 20 mM sodium phosphate buffered water, pH 7.4, room temperature. 
 
4.7 Commentary on the Tabulated Ka Values. 
The Ka values measured for the various hosts and guests in this study 
ranged from 6.2 × 10
3




, with IV-1 being the highest affinity host 
toward each guest. In general, the presence of an alkyl linker and the loss of two 
sulfonate groups led to a decrease in binding affinity of IV-2a - IV-2c toward IV-
6 – IV-10 relative to IV-1 by one or two orders of magnitude. The lowered 
electrostatic attraction between the dianionic hosts and monocationic guests as 
compared to that between the tetraanionic IV-1 and the same guests; as well as 
the energetic penalty of displacing the alkyl linker from within the cavities the 
new hosts/ decreased cavity volume led to significant losses in binding affinities. 
The preference for CB[n] hosts to bind hexyl diammonium ions is well known, 
due to the size complementarity which leads to the positioning of the hydrophobic 
Guest 
Binding Constants (M-1), ΔH (kcal mol-1) with various molecular containers  
1             2a            2b 2c 
6 (2.4 ± 0.1) × 10
6, -8.7 (6.2 ± 0.9) × 103, -3.9 (1.3 ± 0.1) × 105, -5.5 (2.3 ± 0.2) × 104, -5.0 
7  (1.7 ± 0.1) × 10
6, -8.2 (2.3 ± 0.2) × 104, -8.7 (7.9 ± 0.1) × 105, -8.6 (3.2 ± 0.3) × 104, -6.0  
8 (3.9 ± 0.2) × 10
6, -10.5 (2.1 ± 0.1) × 104, -11.3 (1.6 ± 0.1) × 106, -9.5 (7.1 ± 0.4) × 104, -8.5 
9 (4.9 ± 0.2) × 10
5, -7.1 (2.7 ± 0.6) × 104, -4.5 (7.2 ± 1.0) × 105, -3.9 (1.5 ± 0.04) × 104, -6.5 
10  (6.2 ± 0.6) × 10
6, -9.0 (6.9 ± 0.3) × 104, -6.9 (1.3 ± 0.03) × 106, -9.6 (2.7 ± 0.2) × 105, -5.7 







hexyl chain to span the full height of the cavity of the CB[n] while the ammonium 
groups are appropriately placed for ion-dipole interactions with the carbonyl 
portals on each end.
18
 The same preference has been reported for IV-1 and its 
analogues.
37





However, hosts IV-2a – IV-2c show a drastically lowered preference for IV-6. In 
case of IV-2b and IV-2c the 19- and 104-fold loss in affinity respectively, can be 
explained by the cost of displacing the hexyl and still longer decyl linkers from 
the cavity to accommodate the hexyl chain of IV-8. In case of IV-2a, the shorter 
ethyl linker brings one end of the aromatic walls close together reducing the 
cavity volume.  Therefore, guest IV-6 has to be accommodated within the cavity 
of IV-2a of reduced volume, leading to a 387-fold decrease in affinity relative to 
IV-1. Guest IV-7 being shorter and wider than IV-6 is preferred by IV-2a and 
IV-2b over IV-6 on account of their decreased cavity depths due to the presence 
of the alkyl linker. Predictably, host IV-1 which has no such factors decreasing its 
cavity volume shows little preference between IV-6 and IV-7. Interestingly, IV-
2c also shows little preference for IV-7 over IV-6. This lack of selectivity can be 
attributed to the larger decyl linker, which would need to be pushed out from the 
cavity to accommodate either guest IV-6 or IV-7 and the energetic penalty is 
same for both.  
For each of the hosts in this study, guest IV-8 results in one of the tightest 
complexes from group of guests IV-6 – IV-10 due to its aromatic ring which can 
undergo favorable π-π interactions with the aromatic walls of each host molecule. 







IV-10 over the primary ammonium adamantyl guest IV-9. This selectivity is most 
pronounced for IV-1 (13-fold). We rationalize this selectivity based on the 
improved ion-dipole interactions between the N-methyl ammonium groups with 
the ureidyl carbonyl portal of the host. For hosts IV-2a – IV-2c we only observe a 
2-3 fold selectivity for IV-10 over IV-9. This can be explained based on the 
partial encapsulation of IV-9 and IV-10 in the cavities of IV-2a – IV-2c on 
account of the decreased cavity volumes of these hosts. The evidence for partial 
encapsulation comes from the 
1
H NMR resonance of the methyl protons of IV-10 
when bound to IV-2a – IV-2c. This resonance does not undergo upfield shifting 
in their host-guest complexes (Appendix 3), indicating that IV-10 is not 
encapsulated within the host cavities. In contrast, the 
1
H NMR resonance of the 
same N-methyl protons when bound to IV-1 undergoes a substantial upfield 
shifting potentially due to the out of plane helicity for IV-1 leading to a shielding 
effect by one of its aromatic walls. Therefore, the presence or absence of methyl 
groups on the ammonium nitrogen protruding outside of the cavities of IV-2a –
IV-2c does not significantly affect their binding affinities.  
4.8 Conclusions. 
Three new hosts IV-2a – IV-2c were synthesized with alkyl linkers of varying 
lengths- ethyl, hexyl, and decyl; capping one end of the previously reported host 
IV-1. These new hosts were less water soluble than IV-1 due to the loss of two 
sulfonate groups and did not undergo intermolecular self-association. However, 
the intramolecular self-inclusion of the alkyl linkers inside the cavity of these 







work will try to overcome these disadvantages in the solubility and molecular 
recognition properties of IV-2a – IV-2c by incorporating linkers with more 
rigidity and/or hydrophilic groups that do not undergo self-inclusion processes, 
such as aromatic walls connected by oligoethylene glycol units. Such linkers 
would lead to entropic gains from the improved preorganization of the acyclic 
CB[n] cavity and enthalpic gains from the favorable interactions between the 
capping linker and encapsulated guest; without the energetic penalty of self-
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General experimental details.  Drugs used for measuring binding constants with 
II-2 were purchased from commercial suppliers and used without further 




H NMR spectra were measured on commercial spectrometers operating at 400 or 
600 MHz.  UV-Vis absorbance was measured on a Varian Cary 100 UV 
spectrophotometer. 
 
Determination of Ka between Host II-2 with various drugs using UV/Vis 




 can be measured reliably by 
1
H NMR 
spectroscopic methods. For values that exceed this level it is necessary to use 
other techniques such as UV/Vis, fluorescence, or isothermal titration calorimetry. 
UV/Vis spectroscopy was used in this work.  
The Ka between II-2 and II-4 (tetracycline, UV/Vis active drug) was determined 
by direct titration of a fixed concentration of II-4 with increasing concentrations 
of II-2. The Ka value was determined by fitting the change in absorbance as a 
function of host concentration to a 1:1 binding model. In order to determine the 
Ka value for II-2 toward guests which were not UV/Vis active, an indicator 
displacement assay involving the addition of guest to a solution of II-2 and dye 
Rhodamine 6G was used. The change in UV/Vis absorbance as a function of 
guest concentration was fitted to a competitive binding model which allowed 
determination of the Ka values based on the known total concentrations of II-2, 
Rhodamine 6G, and drug. The known Ka value of the II-2•Rhodamine 6G 













Binding Models Used to Determine Values of Ka with Micromath Scientist 
 
1:1 Binding Model for UV/Vis. 
// Micromath Scientist Model File 
// 1:1 Host:Guest binding model 




Params: Ka, ConcGuestTot, SpectroscopicSignalMin, SpectroscopicSignalMax 
Ka = ConcHostGuest/(ConcHostFree*ConcGuestFree) 
ConcHostTot=ConcHostFree + ConcHostGuest 
ConcGuestTot=ConcGuestFree + ConcHostGuest 
SpectroscopicSignal = SpectroscopicSignalMin + (SpectroscopicSignalMax - 
SpectroscopicSignalMin) * (ConcHostGuest/ConcGuestTot) 
//Constraints 
0 < ConcHostFree < ConcHostTot 
0 < Ka 
0 < ConcGuestFree < ConcGuestTot 
0 < ConcHostGuest < ConcHostTot 
 
Competitive Binding (Indicator Displacement) Models. 
 
Competitive Model Fitting Absorbance at One Wavelength. 
// MicroMath Scientist Model File 
IndVars: ConcAntot 
DepVars: Absorb 
Params: ConcHtot, ConcGtot, Khg, Kha, AbsorbMax, AbsorbMin 
Khg = ConcHG / (ConcH * ConcG) 
Kha = ConcHAn / (ConcH * ConcAn) 
Absorb = AbsorbMin + (AbsorbMax-AbsorbMin)*(ConcHG/ConcGtot) 
ConcHtot = ConcH + ConcHG + ConcHAn 
ConcGtot = ConcHG + ConcG 
ConcAntot = ConcAn + ConcHAn 
0 < ConcHG < ConcHtot 
0 < ConcH < ConcHtot 
0 < ConcG < ConcGtot 
0 < ConcAn < ConcAntot 
*** 
 
Competitive Model Fitting Absorbance at Two Wavelengths. 
// MicroMath Scientist Model File 
IndVars: ConcAntot 







Params:Khg, Kha, AbsorbMax1, AbsorbMin1, AbsorbMax2, AbsorbMin2 
Khg = ConcHG / (ConcH * ConcG) 
Kha = ConcHAn / (ConcH * ConcAn) 
Absorb1 = AbsorbMin1 + (AbsorbMax1-AbsorbMin1)*(ConcHG/0.00001) 
Absorb2 = AbsorbMin2 + (AbsorbMax2-AbsorbMin2)*(ConcHG/0.00001) 
0.00001 = ConcH + ConcHG + ConcHAn 
0.00001= ConcHG + ConcG 
ConcAntot = ConcAn + ConcHAn 
0 < ConcHG < 0.00001 
0 < ConcH < 0.00001 
0 < ConcG < 0.00001 













Figure II-S1. (A) UV/Vis spectra from the titration of II-2 (0–610 µM) with 
guest II-4 (57.3 µM) in 20 mM NaH2PO4 buffer (pH = 7.4); (B) plot of the A390 as 
a function of the concentration of II-2. The solid line represents the best non-















Figure II-S2. (A) UV/Vis spectra from the titration of II-2 (5.07 µM) and 
Rhodamine 6G (5.01 µM) with guest II-8 (0 – 6.08 mM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-8. 
The solid line represents the best non-linear fit of the data to a competitive 














   
 
 
Figure II-S3. (A) UV/Vis spectra from the titration of II-2 (10.1 µM) and 
Rhodamine 6G (9.96 µM) with guest II-10 (0 – 4.32 mM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-10. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S4. (A) UV/Vis spectra from the titration of II-2 (9.98 µM) and 
Rhodamine 6G (9.96 µM) with guest II-12 (0 – 1.11 mM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-12. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S5. (A) UV/Vis spectra from the titration of II-2 (10.2 µM) and 
Rhodamine 6G (9.96 µM) with guest II-14 (0 – 447 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-14. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S6. (A) UV/Vis spectra from the titration of II-2 (9.92 µM) and 
Rhodamine 6G (10.0 µM) with guest II-15 (0 – 2.05 mM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-15. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S7. (A) UV/Vis spectra from the titration of II-2 (9.92 µM) and 
Rhodamine 6G (10.0 µM) with guest II-16 (0 – 1.32 mM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-16. 
The solid line represents the best non-linear fit of the data to a competitive 
















Figure II-S8. (A) UV/Vis spectra from the titration of II-2 (10.1 µM) and 
Rhodamine 6G (9.96 µM) with guest II-17 (0 – 486 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-17. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S9. (A) UV/Vis spectra from the titration of II-2 (10.2 µM) and 
Rhodamine 6G (9.96 µM) with guest II-18 (0 – 686 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-18. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S10. (A) UV/Vis spectra from the titration of II-2 (10.2 µM) and 
Rhodamine 6G (10.3 µM) with guest II-19 (0 – 510 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-19. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S11. (A) UV/Vis spectra from the titration of II-2 (5.07 µM) and 
Rhodamine 6G (5.01 µM) with guest II-20 (0 – 107 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-20. 
The solid line represents the best non-linear fit of the data to a competitive 
















Figure II-S12. (A) UV/Vis spectra from the titration of II-2 (12.5 µM) and 
Rhodamine 6G (12.4 µM) with guest II-21 (0 –131µM) in 20mM NaH2PO4 buffer 
(pH = 7.4); (B) plot of the A550 as a function of the concentration of II-21. The 
solid line represents the best non-linear fit of the data to a competitive binding 
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Figure II-S13. (A) UV/Vis spectra from the titration of II-2 (9.92 µM) and 
Rhodamine 6G (10.0 µM) with guest II-22 (0 – 968 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-22. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S14. (A) UV/Vis spectra from the titration of II-2 (5.07 µM) and 
Rhodamine 6G (5.01 µM) with guest II-23 (0 – 616 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-23. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S15. (A) UV/Vis spectra from the titration of II-2 (5.07 µM) and 
Rhodamine 6G (5.01 µM) with guest II-24 (0 – 237 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-24. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S16. (A) UV/Vis spectra from the titration of II-2 (10.1 µM) and 
Rhodamine 6G (9.96 µM) with guest II-25 (0 – 345 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-25. 
The solid line represents the best non-linear fit of the data to a competitive 














Figure II-S17. (A) UV/Vis spectra from the titration of II-2 (10.1 µM) and 
Rhodamine 6G (9.96 µM) with guest II-26 (0 – 450 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-26. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S18. (A) UV/Vis spectra from the titration of II-2 (9.92 µM) and 
Rhodamine 6G (10.0 µM) with guest II-27 (0 – 552 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-27. 
The solid line represents the best non-linear fit of the data to a competitive 

















Figure II-S19. (A) UV/Vis spectra from the titration of II-2 (9.92 µM) and 
Rhodamine 6G (10.0 µM) with guest II-28 (0 – 1.21 mM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-28. 
The solid line represents the best non-linear fit of the data to a competitive 















Figure II-S20. (A) UV/Vis spectra from the titration of II-2 (5.07 µM) and 
Rhodamine 6G (5.01 µM) with guest II-29 (0 – 14.2 µM) in 20 mM NaH2PO4 
buffer (pH = 7.4); (B) plot of the A550 as a function of the concentration of II-29. 
The solid line represents the best non-linear fit of the data to a competitive 











1:1 Binding Models for NMR 
 
Model Fitting Absorbance at One Chemical Shift. 
// Micromath Scientist Model File 
// 1:1 Host:Guest binding model for NMR 




Params: Ka, ConcGuestTot, Deltasat, Deltazero 
Ka = ConcHostGuest/(ConcHostFree*ConcGuestFree) 
ConcHostTot=ConcHostFree + ConcHostGuest 
ConcGuestTot=ConcGuestFree + ConcHostGuest 
Deltaobs = Deltazero + (Deltasat - Deltazero) * (ConcHostGuest/ConcGuestTot) 
//Constraints 
0 < ConcHostFree < ConcHostTot 
0 < Ka 
0 < ConcGuestFree < ConcGuestTot 
0 < ConcHostGuest < ConcHostTot 
*** 
 
Model Fitting Absorbance at Two Chemical Shifts. 
// Micromath Scientist Model File 
IndVars: ConcHost 
DepVars: CSA, CSB 
Params: Ka, CSAzero, CSAsat, CSBzero, CSBsat 
Ka = ConcHG/(ConcHfree*ConcGfree) 
ConcHost=ConcHfree+ConcHG 
0.0001=ConcGfree+ConcHG 
CSA = CSAzero + ((CSAsat-CSAzero)*(ConcHG/0.0001)) 
















Figure II-S21. (A) 
1
H NMR (600 MHz) stack plot of the titration of II-2 (0.104 
mM) with guest II-3 (0 - 1.03 mM) in 20 mM NaH2PO4 buffered D2O (pH = 7.4); 
(B) plot of the chemical shift at 7.67 ppm as a function of guest concentration. 
The solid line represents the best non-linear fit of the data to a 1:1 model (Ka = 















Figure II-S22. (A) 
1
H NMR (600 MHz) stack plot of the titration of II-2 (0 - 4.5 
mM) with guest II-5 (1.86 mM) in 20 mM NaH2PO4 buffered D2O (pH = 7.4); 
(B) plot of the chemical shift at 1.46 ppm as a function of host concentration. The 
















Figure II-S23. (A) 
1
H NMR (400 MHz) stack plot of the titration of II-2 (0.976 
mM) with guest II-6 (0 - 7.24 mM) in 20 mM NaH2PO4 buffered D2O (pH = 7.4); 
(B) plot of the chemical shift at 7.17 ppm as a function of guest concentration. 
The solid line represents the best non-linear fit of the data to a 1:1 model (Ka = 















Figure II-S24. (A) 
1
H NMR (600 MHz) stack plot of the titration of II-2 (0.199 
mM) with guest II-7 (0 - 1.26 mM) in 20 mM NaH2PO4 buffered D2O (pH = 7.4); 
(B) plot of the chemical shift at 7.69 ppm as a function of guest concentration. 
The solid line represents the best non-linear fit of the data to a 1:1 model (Ka = 















Figure II-S25. (A) 
1
H NMR (600 MHz) stack plot of the titration of II-2 (1.50 
mM) with guest II-9 (0 - 2.7 mM) in 20 mM NaH2PO4 buffered D2O (pH = 7.4); 
(B) plot of the chemical shift at 7.15 and 7.72 ppm as a function of guest 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 















Figure II-S26. (A) 
1
H NMR (600 MHz) stack plot of the titration of II-22 (0.150 
mM) with guest II-11 (0 - 1.3 mM) in 20 mM NaH2PO4 buffered D2O (pH = 7.4); 
(B) plot of the chemical shift at 7.12 and 7.68 ppm as a function of guest 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 
















Figure II-S27. (A) 
1
H NMR (600 MHz) stack plot of the titration of II-2 (0.150 
mM) with guest II-13 (0 - 1.26 mM) in 20 mM NaH2PO4 buffered D2O (pH = 
7.4); (B) plot of the chemical shift at 7.12 and 7.68 ppm as a function of guest 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 
















H NMR spectra recorded (400 MHz, RT, D2O) for a) II-3, b) II-
2, c) an equimolar mixture of II-2 and II-3 (5 mM), and d) a 1:2 mixture of II-2 












H NMR spectra recorded (400 MHz, RT, D2O) for a) II-4, b) II-
2, c) an equimolar mixture of II-2 and II-4 (12.5 mM), and d) a 1:2 mixture of II-











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-5, b) II-
2, c) an equimolar mixture of II-2 and II-5 (5 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-6, b) II-
2, c) an equimolar mixture of II-2 and II-6 (12.5 mM), and d) a 1:2 mixture of II-











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-7, b) II-
2, c) an equimolar mixture of II-2 and II-7 (5 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-8, b) II-
2, c) an equimolar mixture of II-2 and II-8 (5 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-9, b) II-
2, c) an equimolar mixture of II-2 and II-9 (5 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-10, b) II-
2, c) an equimolar mixture of II-2 and II-10 (4 mM), and d) a 1:2 mixture of II-2 










H NMR spectra recorded (400 MHz, RT, D2O) for a) II-11, b) II-
2, c) an equimolar mixture of II-2 and II-11 (4 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-12, b) II-
2, c) an equimolar mixture of II-2 and II-12 (4 mM), and d) a 1:2 mixture of II-2 










H NMR spectra recorded (400 MHz, RT, D2O) for a) II-13, b) II-
2, c) an equimolar mixture of II-2 and II-13 (12.5 mM), and d) a 1:2 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-14, b) II-
2, c) an equimolar mixture of II-2 and II-14 (4 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-15, b) II-
2, c) an equimolar mixture of II-2 and II-15 (12.5 mM), and d) a 1:2 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-16, b) II-
2, and c) an equimolar mixture of II-2 and II-16 (2 mM), and d) a 1:2 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-17, b) II-











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-18, b) II-
2, c) an equimolar mixture of II-2 and II-18 (4 mM), and d) a 1:2 mixture of II-2 













H NMR spectra recorded (400 MHz, RT, D2O) for a) II-19, b) II-
2, c) an equimolar mixture of II-2 and II-19 (4 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-20, b) II-
2, c) an equimolar mixture of II-2 and II-20 (5 mM), and d) a 1:2 mixture of II-2 










H NMR spectra recorded (400 MHz, RT, D2O) for a) II-21, b) II-
2, and c) an equimolar mixture of II-2 and II-21 (4 mM), and d) a 1:2 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-22, b) II-
2, c) an equimolar mixture of II-2 and II-22 (12.5 mM), and d) a 1:2 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-23, b) II-
2, c) an equimolar mixture of II-2 and II-23 (5 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-24, b) II-
2, c) an equimolar mixture of II-2 and II-24 (5 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-25, b) II-
2, and c) an equimolar mixture of II-2 and II-25 (2 mM), and d) a 1:2 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-26, b) II-
2, c) an equimolar mixture of II-2 and II-26 (4 mM), and d) a 1:2 mixture of II-2 










H NMR spectra recorded (400 MHz, RT, D2O) for a) II-27, b) II-
2, c) an equimolar mixture of II-2 and II-27 (5 mM), and d) a 1:2 mixture of II-2 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-28, b) II-
2, c) an equimolar mixture of II-2 and II-28 (12.5 mM), and d) a 1:2 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for a) II-29, b) II-
2, c) an equimolar mixture of II-2 and II-29 (5 mM), and d) a 1:2 mixture of II-2 









Figure II-S55. Job plot establishing 1:1 binding of II-6 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1
H NMR (400 MHz, D2O). 
 
 
Figure II-S56. Job plot establishing 1:1 binding of II-7 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1








Figure II-S57. Job plot establishing 1:1 binding of II-13 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1




Figure II-S58. Job plot establishing 1:1 binding of II-15 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1








Figure II-S59. Job plot establishing 1:1 binding of II-20 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1
H NMR (400 MHz, D2O). 
 
 
Figure II-S60. Job plot establishing 1:1 binding of II-21 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1









Figure II-S61. Job plot establishing 1:1 binding of II-22 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1
H NMR (400 MHz, D2O). 
 
 
Figure II-S62. Job plot establishing 1:1 binding of II-23 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1










Figure II-S63. Job plot establishing 1:1 binding of II-28 (0 - 1 mM) with II-2 (0 - 
1 mM) based on change in chemical shift of 
1

















Figure II-S64. Three dimensional surface plot of the equilibrium mole fraction of 
AChR•vecuronium versus log [Drug] and log K3 for vecuronium at [Vecuronium] 













Figure II-S65. Three dimensional surface plot of the equilibrium mole fraction of 
AChR•cisatracurium versus log [Drug] and log K3 at [Cisatracurium] = [AChR] = 








. The red dots 









Figure II-S66. Three dimensional surface plot of the equilibrium mole fraction of 
AChR•cistracurium versus log [Drug] and log K3 at [Cisatracurium] = [AChR] = 








. The red dots 












Figure II-S67. Probable pathway for the Hoffmann degradation of cisatracurium 
to laudanosin and pentamethylene diacrylate. 
 
The Hoffmann degradation of cisatracurium was studied in the Krebs-
Henseleit buffer (pH = 7.4, 37.5 °C), using 
1
H-NMR. The Krebs-Henseleit buffer 
consisted of the following dissolved in deuterium oxide (D2O): monopotassium 
phosphate (1.0 mM), magnesium sulphate heptahydrate (0.6 mM), potassium 
chloride (5.0 mM), sodium bicarbonate (30.0 mM), α-D-glucose monohydrate 
(20.0 mM), sodium chloride (118 mM), and calcium chloride (2.5 mM). 
Figure II-S67 shows the most probable pathway for the degradation of 







A 3.5 mM solution of cisatracurium in Krebs-Henseleit buffer was 
monitored by 
1
H NMR every 10 min for 1 hour, and then hourly for 5 h. The last 
reading was taken 24 hours after the solution was prepared.  
The conversion of cisatracurium into pentamethylene diacrylate was monitored by 
the appearance of its characteristic alkene proton peaks: Hx (2H, 6.35 ppm), Hy 
(2H, 6.13 ppm), and Hz (2H, 6.56 ppm), which increased in intensity over time. 
The peaks for Ha (4H, 1.90 ppm) and Hb (2H, 1.63 ppm) in cisatracurium overlap 
with those of pentamethylene diacrylate; hence their integrals represent the total 
concentration of cisatracurium added. These integrals can be compared to those of 
Hx, Hy, and Hz to quantify the extent of degradation with time. 
 
 

















































H NMR spectra recorded (600 MHz, 37.5 °C, Krebs-Henseleit 
buffer in D2O at pH = 7.4) for 3.5 mM cisatracurium at: a) 10 min, b) 1 h, c) 6 h, 
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General experimental details.  
Drugs used for measuring binding constants, host p-sulfo calix[4]arene, and 
hydroxypropyl β-cyclodextrin (HP-β-CD) were purchased from commercial 
suppliers and used without further purification. Calabadion 1, Calabadion 2, and 




H NMR spectra 
were measured on Bruker instruments operating at 400 or 600 MHz. UV/Vis 
spectra were measured on a Varian Cary 100 UV spectrophotometer. ITC data 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
methamphetamine, b) Calabadion 1, c) an equimolar mixture of 
methamphetamine and Calabadion 1 (1 mM), and d) a 2:1 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
methamphetamine, b) Calabadion 2, c) an equimolar mixture of 
methamphetamine and Calabadion 2 (2 mM), and d) a 2:1 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
methamphetamine, b) CB[7], c) an equimolar mixture of methamphetamine and 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
methamphetamine, b) p-sulfo calix[4]arene, c) an equimolar mixture of 
methamphetamine and p-sulfo calix[4]arene (2 mM), and d) a 2:1 mixture of 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
methamphetamine, b) HP-β-CD, c) an equimolar mixture of methamphetamine 
and HP-β-CD (1 mM), and d) a 2:1 mixture of methamphetamine (2 mM) and 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) fentanyl, b) 
Calabadion 1, c) an equimolar mixture of fentanyl and Calabadion 1 (1 mM), and 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) fentanyl, b) 
Calabadion 2, c) an equimolar mixture of fentanyl and Calabadion 2 (1 mM), and 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) fentanyl, b) 
CB[7], c) an equimolar mixture of methamphetamine and fentanyl (1 mM), and d) 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) fentanyl, b) 
p-sulfo calix[4]arene, c) an equimolar mixture of fentanyl and p-sulfo 
calix[4]arene (1 mM), and d) a 2:1 mixture of fentanyl (2 mM) and p-sulfo 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) fentanyl, 
b) HP-β-CD, c) an equimolar mixture of fentanyl and HP-β-CD (1 mM), and d) a 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) cocaine, 
b) Calabadion 1, c) an equimolar mixture of cocaine and Calabadion 1 (2 mM), 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) cocaine, 
b) Calabadion 2, c) an equimolar mixture of cocaine and Calabadion 2 (2 mM), 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) cocaine, 
b) CB[7], c) an equimolar mixture of cocaine and CB[7] (2 mM), and d) a 2:1 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) cocaine, 
b) p-sulfo calix[4]arene, c) an equimolar mixture of cocaine and p-sulfo 
calix[4]arene (2 mM), and d) a 2:1 mixture of cocaine (2 mM) and p-sulfo 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) cocaine, 
b) HP-β-CD, c) an equimolar mixture of cocaine and HP-β-CD (1 mM), and d) a 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) ketamine, 
b) Calabadion 1, c) an equimolar mixture of ketamine and Calabadion 1 (1 mM), 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) ketamine, 
b) Calabadion 2, c) an equimolar mixture of ketamine and Calabadion 2 (1 mM), 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) ketamine, 
b) CB[7], c) an equimolar mixture of ketamine and fentanyl (1 mM), and d) a 2:1 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) ketamine, 
b) p-sulfo calix[4]arene, c) an equimolar mixture of ketamine and p-sulfo 
calix[4]arene (1 mM), and d) a 2:1 mixture of ketamine (2 mM) and p-sulfo 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) ketamine, 
b) HP-β-CD, c) an equimolar mixture of ketamine and HP-β-CD (1 mM), and d) a 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
phencyclidine, b) Calabadion 1, c) an equimolar mixture of phencyclidine and 
Calabadion 1 (2 mM), and d) a 2:1 mixture of phencyclidine (2 mM) and 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
phencyclidine, b) Calabadion 2, c) an equimolar mixture of phencyclidine and 
Calabadion 2 (2 mM), and d) a 2:1 mixture of phencyclidine (2 mM) and 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
phencyclidine, b) CB[7], c) an equimolar mixture of phencyclidine and CB[7] (2 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
phencyclidine, b) p-sulfo calix[4]arene, c) an equimolar mixture of phencyclidine 
and p-sulfo calix[4]arene (2 mM), and d) a 2:1 mixture of phencyclidine (2 mM) 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
phencyclidine, b) HP-β-CD, c) an equimolar mixture of phencyclidine and HP-β-












H NMR spectra recorded (400 MHz, RT, D2O) for: a) morphine, 
b) Calabadion 1, c) an equimolar mixture of morphine and Calabadion 1 (2 mM), 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) morphine, 
b) Calabadion 2, c) an equimolar mixture of morphine and Calabadion 2 (2 mM), 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) morphine, 
b) CB[7], c) an equimolar mixture of morphine and CB[7] (2 mM), and d) a 2:1 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) morphine, 
b) p-sulfo calix[4]arene, c) an equimolar mixture of morphine and p-sulfo 
calix[4]arene (2 mM), and d) a 2:1 mixture of morphine (2 mM) and p-sulfo 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) morphine, 
b) HP-β-CD, c) an equimolar mixture of morphine and HP-β-CD (1 mM), and d) 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
hydromorphone, b) Calabadion 1, c) an equimolar mixture of hydromorphone and 
Calabadion 1 (1 mM), and d) a 2:1 mixture of f hydromorphone (2 mM) and 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
hydromorphone, b) Calabadion 2, c) an equimolar mixture of hydromorphone and 
Calabadion 2 (1 mM), and d) a 2:1 mixture of hydromorphone (2mM) and 











H NMR spectra recorded (400MHz, RT, D2O) for: a) 
hydromorphone, b) CB[7], c) an equimolar mixture of hydromorphone and 











H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
hydromorphone, b) p-sulfo calix[4]arene, c) an equimolar mixture of 
hydromorphone and p-sulfo calix[4]arene (1 mM), and d) a 2:1 mixture of 












H NMR spectra recorded (400 MHz, RT, D2O) for: a) 
hydromorphone, b) HP-β-CD, c) an equimolar mixture of hydromorphone and 








Determination of Ka between hosts Calabadion 1 and Calabadion 2 and 
various drugs of abuse using UV/Vis spectroscopy.  




 can be measured by direct 
1
H NMR titration. For values 
that exceed this level it is necessary to use other techniques such as UV/Vis, 
fluorescence, or isothermal titration calorimetry. UV/Vis spectroscopy was used 
in this work.  
In order to determine the Ka value for Calabadion 1 and Calabadion 2 toward 
UV/Vis inactive drugs of abuse, an indicator displacement assay involving the 
addition of drug to a solution of host and dye rhodamine 6G was used. The 
change in UV/Vis absorbance as a function of drug concentration was fitted to a 
competitive binding model which allowed determination of the Ka values. The 
























Competitive Binding (Indicator Displacement) Model Used to Determine 
Values of Ka with MicroMath Scientist 
// MicroMath Scientist Model File 
IndVars: ConcAntot 
DepVars: Absorb 
Params: ConcHtot, ConcGtot, Khg, Kha, AbsorbMax, AbsorbMin 
Khg = ConcHG / (ConcH * ConcG) 
Kha = ConcHAn / (ConcH * ConcAn) 
Absorb = AbsorbMin + (AbsorbMax-AbsorbMin)*(ConcHG/ConcGtot) 
ConcHtot = ConcH + ConcHG + ConcHAn 
ConcGtot = ConcHG + ConcG 
ConcAntot = ConcAn + ConcHAn 
0 < ConcHG < ConcHtot 
0 < ConcH < ConcHtot 
0 < ConcG < ConcGtot 
0 < ConcAn < ConcAntot 
*** 
 
// MicroMath Scientist Model File 
IndVars: ConcAntot 
DepVars: Absorb1, Absorb2 
Params:Khg, Kha, AbsorbMax1, AbsorbMin1, AbsorbMax2, AbsorbMin2 
Khg = ConcHG / (ConcH * ConcG) 
Kha = ConcHAn / (ConcH * ConcAn) 
Absorb1 = AbsorbMin1 + (AbsorbMax1-AbsorbMin1)*(ConcHG/0.00001) 
Absorb2 = AbsorbMin2 + (AbsorbMax2-AbsorbMin2)*(ConcHG/0.00001) 
0.00001 = ConcH + ConcHG + ConcHAn 
0.00001= ConcHG + ConcG 
ConcAntot = ConcAn + ConcHAn 
0 < ConcHG < 0.00001 
0 < ConcH < 0.00001 
0 < ConcG < 0.00001 






















Figure III-S36. a) UV/Vis spectra from the titration of Calabadion 1 (5.02 µM) 
and rhodamine 6G (4.97 µM) with guest methamphetamine (0 – 581 µM) in 20 
mM NaH2PO4 buffer (pH 7.4); b) plot of the A550 as a function of 
methamphetamine concentration. The solid line represents the best non-linear fit 

















Figure III-S37. a) UV/Vis spectra from the titration of Calabadion 2 (4.97 µM) 
and rhodamine 6G (4.97 µM) with guest methamphetamine (0 – 219 µM) in 20 
mM NaH2PO4 buffer (pH 7.4); b) plot of the A550 as a function of 
methamphetamine  concentration. The solid line represents the best non-linear fit 



















Figure III-S38. a) UV/Vis spectra from the titration of Calabadion 1 (5.02 µM) 
and rhodamine 6G (4.97 µM) with guest cocaine (0 – 885 µM) in 20 mM 
NaH2PO4 buffer (pH 7.4); b) plot of the A550 as a function of cocaine 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 


















Figure III-S39. a) UV/Vis spectra from the titration of Calabadion 2 (4.97 µM) 
and rhodamine 6G (4.97 µM) with guest cocaine (0 – 745 µM) in 20 mM 
NaH2PO4 buffer (pH 7.4); b) plot of the A550 as a function of cocaine 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 















Figure 40. a) UV/Vis spectra from the titration of Calabadion 1 (5.01 µM) and 
rhodamine 6G (4.96 µM) with ketamine (0 – 2.44 mM) in 20 mM NaH2PO4 
buffer (pH = 7.4); b) plot of the A550 as a function of the concentration of 
ketamine. The solid line represents the best non-linear fit of the data to a 



















Figure 41. a) UV/Vis spectra from the titration of Calabadion 2 (9.18 µM) and 
rhodamine 6G (10.00 µM) with ketamine (0 – 0.35 mM) in 20 mM NaH2PO4 
buffer (pH = 7.4); b) plot of the A550 as a function of the concentration of 
ketamine. The solid line represents the best non-linear fit of the data to a 

















Figure III-S42. a) UV/Vis spectra from the titration of Calabadion 1 (5.02 µM) 
and rhodamine 6G (4.97 µM) with guest phencyclidine (0 – 1.62 mM) in 20 mM 
NaH2PO4 buffer (pH 7.4); b) plot of the A550 as a function of phencyclidine  
concentration. The solid line represents the best non-linear fit of the data to a 1:1 
















Figure III-S43. a) UV/Vis spectra from the titration of Calabadion 2 (4.97 µM) 
and rhodamine 6G (4.97 µM) with guest phencyclidine (0 – 1.24 mM) in 20 mM 
NaH2PO4 buffer (pH 7.4); b) plot of the A550 as a function of phencyclidine 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 

















Figure III-S44. a) UV/Vis spectra from the titration of Calabadion 1 (5.00 µM) 
and rhodamine 6G (5.01 µM) with guest morphine (0 – 1.58 mM) in 20 mM 
NaH2PO4 buffer (pH 7.4); b) plot of the A550 as a function of morphine 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 
















Figure III-S45. a) UV/Vis spectra from the titration of Calabadion 2 (5.07 µM) 
and rhodamine 6G (5.01 µM) with guest morphine (0 – 107 µM) in 20 mM 
NaH2PO4 buffer (pH 7.4); b) plot of the A550 as a function of morphine 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 












Determination of Ka between hosts CB[7] and p-sulfo calix[4]arene and 
various drugs of abuse using 
1
H NMR.  




were determined by 
direct 
1
H NMR titrations. The concentration of either the host or guest was kept 
constant while varying the concentration of the other component. The change in 
chemical shift of a selected signal of the species whose concentration was fixed 
was monitored. The change in chemical shift as a function of the concentration of 
the species being varied was fitted to a 1:1 binding model to determine the Ka.  
1:1 Binding Model for NMR 
 
// Micromath Scientist Model File 
// 1:1 Host:Guest binding model 




Params: Ka, ConcGuestTot, SpectroscopicSignalMin, SpectroscopicSignalMax 
Ka = ConcHostGuest/(ConcHostFree*ConcGuestFree) 
ConcHostTot=ConcHostFree + ConcHostGuest 
ConcGuestTot=ConcGuestFree + ConcHostGuest 
SpectroscopicSignal = SpectroscopicSignalMin + (SpectroscopicSignalMax - 
SpectroscopicSignalMin) * (ConcHostGuest/ConcGuestTot) 
//Constraints 
0 < ConcHostFree < ConcHostTot 
0 < Ka 
0 < ConcGuestFree < ConcGuestTot 
















Figure III-S46. One of the 
1
H NMR (600 MHz) spectra used in the determination 







Sample Determination of Krel for the Competition between TMSP and 
Methamphetamine for CB[7].  
Equation 1 was used to determine Krel for the competition of TMSP and 
methamphetamine for CB[7]. For this purpose, a solution containing CB[7] 
(500.2 μM), TMSP (600.6 μM), and methamphetamine (598.7 μM) was prepared 
and allowed to reach equilibrium (Figure III-S46). Next the relative 
concentrations of TMSPfree and CB[7]•TMSP were determined by integration of 
the appropriate resonances in the 
1
H NMR spectrum (Figure III-S46: TMSPfree: -
0.005 ppm; CB[7]•TMSP: -0.700 ppm). Using the relative concentrations and the 
mass balance expression (equation 2) [TMSP]free = 478.5 μM and [CB[7]•TMSP] 
= 122.1 μM were calculated. Equation 3 was then used to calculate 
[CB[7]•methamphetamine] = 378.1 μM using the known value of CB[7]•TMSP.
18
 
Lastly, equation 4 was used to calculate [methamphetamine]free = 220.6 μM using 




Substitution of the values of [CB[7]•TMSP], [TMSP]free, 
[CB[7]•methamphetamine], and [methamphetamine]free into equation 1 gave Krel 
= 6.72. These determinations were done in triplicate from independently prepared 
stock solutions and the average values were used in the calculations of Ka. In 
Krel = ([CB[7]• Methamphetamine][TMSP]free) / ([CB[7]•TMSP][methamphetamine]free)  (1) 
[TMSP]Total = 600.6 μM = [TMSP]free + [CB[7]•TMSP]     (2) 
[CB[7]]Total = 500.2 μM = [CB[7]•TMSP] + [CB[7]•methamphetamine]    (3) 








preparing the solutions for the above determinations a small excess of TMSP was 
used to ensure there is no free CB[7]. The Ka for CB[7]•methamphetamine was 



















Figure III-S47. a) 
1
H NMR stack plot from the titration of methamphetamine 
(111 µM) with host p-sulfo calix[4]arene (0 – 361 µM) in 20 mM NaH2PO4 buffer 
(pD 7.4); b) plot of the change in chemical shift of methamphetamine  at 2.70 
ppm as a function of p-sulfo calix[4]arene concentration. The solid line represents 
















Figure III-S48. a) 
1
H NMR stack plot from the titration of cocaine (103 µM) with 
host CB[7] (0 – 588 µM) in 20 mM NaH2PO4 buffer (pD 7.4); b) plot of the 
change in chemical shift of cocaine at 2.87 ppm as a function of CB[7] 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 

















Figure III-S49. a) 
1
H NMR stack plot from the titration of p-sulfo calix[4]arene 
(350 µM) with guest cocaine (0 – 2.52 mM) in 20 mM NaH2PO4 buffer (pD 7.4); 
b) plot of the change in chemical shift of p-sulfo calix[4]arene at 2.14 ppm as a 
function of cocaine concentration. The solid line represents the best non-linear fit 

















Figure III-S50. (A) 
1
H NMR (600 MHz) stack plot from the titration of ketamine 
(1.00 mM) with host CB[7] (0 – 4.9 mM) in 20 mM NaH2PO4 buffered (pH = 7.4) 
D2O; (B) plot of the chemical shift at 2.3 ppm as a function of host CB[7] 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 

















Figure III-S51. a) 
1
H NMR stack plot from the titration of phencyclidine  (1.00 
mM) with host CB[7] (0 – 6.64 mM) in 20 mM NaH2PO4 buffer (pD 7.4); b) plot 
of the change in chemical shift of phencyclidine  at 3.72 ppm as a function of 
CB[7]. The solid line represents the best non-linear fit of the data to a 1:1 model 

















Figure III-S52. a) 
1
H NMR stack plot from the titration of morphine (100 µM) 
with host p-sulfo calix[4]arene (0 – 498 µM) in 20 mM NaH2PO4 buffer (pD 7.4); 
b) plot of the change in chemical shift of morphine at 5.41 ppm and 5.77 ppm as a 
function of p-sulfo calix[4]arene concentration. The solid line represents the best 













Determination of Ka between various hosts and drugs of abuse using 
Isothermal Titration Calorimetry (ITC). 
 
All ITC experiments were conducted in the 200 μL working volume of the sample 
cell of the PEAQ ITC instrument.  We used an injection syringe of 40 μL 
capacity. In each case, the host and guest solutions were prepared in a 20 mM 
NaH2PO4 buffer (pH 7.4). The sample cell was filled to capacity (200 μL) with the 
host solution and the guest solution was titrated in (first injection = 0.4μL, 
subsequent 18 injections = 2 μL). In case of Figure III-S61 and III-S69 two sets of 
19 injections were concatenated to obtain the binding isotherm. The binding data 








Figure III-S53. a) Plot of DP vs time from the titration of HP-β-CD (3.01 mM) 
and with guest methamphetamine (46.9 mM) in 20 mM NaH2PO4 buffer (pH 7.4); 
b) plot of the ΔH as a function of molar ratio. The solid line represents the best 




, ΔH = 








Figure III-S54. a) Plot of DP vs time from the titration of CB[7] (18.0 µM) and 
with guest fentanyl (0.20 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the 
ΔH as a function of molar ratio. The solid line represents the best non-linear fit of 




, ΔH = - 30.4 ± 0.17 








Figure III-S55. a) Plot of DP vs time from the titration of Calabadion 1 (46.8 
µM) and with guest fentanyl (0.499 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) 
plot of the ΔH as a function of molar ratio. The solid line represents the best non-




, ΔH = - 








Figure III-S57. a) Plot of DP vs time from the titration of Calabadion 2 (100 µM) 
and with guest fentanyl (1.00 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of 
the ΔH as a function of molar ratio. The solid line represents the best non-linear fit 




, ΔH = - 20.2 ± 0.07 








Figure III-S58. a) Plot of DP vs time from the titration of HP-β-CD (506 µM) 
and with guest fentanyl (11.2 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of 
the ΔH as a function of molar ratio. The solid line represents the best non-linear fit 




, ΔH = 5.38 ± 0.58 








Figure III-S59. a) Plot of DP vs time from the titration of p-sulfo calix[4]arene 
(82.4 µM) and with guest fentanyl (1.50 mM) in 20 mM NaH2PO4 buffer (pH 
7.4); b) plot of the ΔH as a function of molar ratio. The solid line represents the 













Figure III-S60. a) Plot of DP vs time from the titration of HP-β-CD(4.69 mM) 
and with guest cocaine (47.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of 
the ΔH as a function of molar ratio. The solid line represents the best non-linear fit 




, ΔH = - 1.60 ± 0.32 









Figure III-S61. a) Plot of DP vs time from the titration of HP-β-CD (1.8 mM) 
and with guest ketamine (18.2 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot 
of the ΔH as a function of molar ratio. The solid line represents the best non-linear 












Figure III-S62. a) Plot of DP vs time from the titration of p-sulfo calix[4]arene 
(101 µM) and with guest ketamine (1.00 mM) in 20 mM NaH2PO4 buffer (pH 
7.4); b) plot of the ΔH as a function of molar ratio. The solid line represents the 













Figure III-S63. a) Plot of DP vs time from the titration of HP-β-CD (502 μM) 
and with guest phencyclidine (24.2 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) 
plot of the ΔH as a function of molar ratio. The solid line represents the best non-




, ΔH = - 








Figure III-S64. a) Plot of DP vs time from the titration of calix[4]arene (101 μM) 
and with guest phencyclidine (1.11 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) 
plot of the ΔH as a function of molar ratio. The solid line represents the best non-




, ΔH = - 








Figure III-S65. a) Plot of DP vs time from the titration of Calabadion 1 (100 µM) 
and with guest hydromorphone (1.00 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) 
plot of the ΔH as a function of molar ratio. The solid line represents the best non-




, ΔH = - 








Figure III-S66. a) Plot of DP vs time from the titration of Calabadion 2 (87 µM) 
and with guest hydromorphone (0.934 mM) in 20 mM NaH2PO4 buffer (pH 7.4); 
b) plot of the ΔH as a function of molar ratio. The solid line represents the best 




, ΔH = 








Figure III-S67. a) Plot of DP vs time from the titration of HP-β-CD (1.7 mM) 
and with guest hydromorphone (26.2 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) 
plot of the ΔH as a function of molar ratio. The solid line represents the best non-




, ΔH = 1.35 








Figure III-S68. a) Plot of DP vs time from the titration of p-sulfo calix[4]arene 
(101 µM) and with guest hydromorphone (2.51 mM) in 20 mM NaH2PO4 buffer 
(pH 7.4); b) plot of the ΔH as a function of molar ratio. The solid line represents 













Figure III-S69. a) Plot of DP vs time from the titration of Calabadion 2 (150 µM) 
and with guest methamphetamine (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); 
b) plot of the ΔH as a function of molar ratio. The solid line represents the best 




, ΔH = 








Figure III-S70. a) Plot of DP vs time from the titration of p-sulfo calix[4]arene 
(98.9 µM) and with guest methamphetamine (1.0 mM) in 20 mM NaH2PO4 buffer 
(pH 7.4); b) plot of the ΔH as a function of molar ratio. The solid line represents 













Job plots of selected hosts with methamphetamine showing 1:1 binding. 
 
 
Figure III-S71. Job plot establishing 1:1 binding of methamphetamine (0-10 
mM) with Calabadion 1 (0-10 mm) based on change in 
1
H NMR chemical shift of 




Figure III-S72. Job plot establishing 1:1 binding of methamphetamine (0-10 
mM) with Calabadion 2 (0-10 mm) based on change in 
1
H NMR chemical shift of 














































































Details of the in vivo experiments. 
Care and Use of Animals.  
All experiments involving rats (21 male Sprague-Dawley rats, weight, mean ± 
SD: 288 ± 14 g) were conducted after approval was obtained from the 
Subcommittee on Research Animal Care at Massachusetts General Hospital, 
Boston, MA (Protocol 2011N00181). Experiments were conducted at the research 
laboratories of the Massachusetts General Hospital, Boston, Massachusetts. All 
institutional guidelines for animal care and usage for research purposes were 
followed. 
General surgical procedures.  
All animals were anesthetized (5% isoflurane for inducation; 1.5% isoflurane for 
maintenance in 70% N2O/ 30% O2) for placement of a tail vein intravenous 
catheter (24 gauge; 19 mm). Rectal temperature was kept stable/ steady at 
37.0±0.1°C using a thermostatic heating pad (FHC, Bowdoinham, ME). After 
placement of the catheter the isoflurane anesthesia was stopped and 30 minutes 
were given to the animal to regain full consciousness. The venous catheter was 
removed after completion of the injections prior to any behavioral testing. All 
animals were tested repeatedly with 72h of break to allow recreation between the 
experiments. 
Behavioral Testing 
All animals were placed within one minute after the last injection in the center of 







activity in the open field was videotaped while it was left undisturbed in the 
testing room.  
The primary endpoint, total distance traveled in the open field, was quantified 
using the video tracking software ANY-maze (version 4.5, Stoelting, Wood Dale, 
IL, USA).  
Statistical Analysis 
Values are given in percent of the placebo + methamphetamine activity level and 
reported as mean ± standard error of the mean unless otherwise specified. 
Statistical analysis was performed using SPSS 22.0 (SPSS Inc. Chicago, IL). 
To evaluate the effect of the testing drugs on locomotor activity, we built multiple 
mixed linear models (MLM) with an identity link function for normally 
distributed probability and defined the intercept as random effects.  
Using the previously described MLM, we tested for a fixed main effect of placebo 
+ methamphetamine vs. baseline on locomotor activity to evaluate if 
methamphetamine induces hyperlocomotion.  
The testing drug’s ability to reverse methamphetamine induced hyperlocomotion 
at different doses was determined by testing the fixed main effect of high dose + 
methamphetamine vs. placebo + methamphetamine and low dose + 
methamphetamine vs. placebo + methamphetamine on locomotor activity, 
respectively.  
In order to ensure that the testing compound itself does not interfere with the 
outcome, we assessed the sole effect of the testing compound at the higher dose 







To evaluate if Calabadion 2’s reversal effect is modified by the time of 
administration (indication) we used the same MLM as previously described and 
tested for the fixed interaction effect of indication and Calabadion 2 dose 
(“prevention/treatment” x “Calabadion 2 dose”). 
 
 
Figure III-S73. Tracking plots illustrating the traveled distance of one rat within 
20 minutes in the open field: A) Baseline, no methamphetamine given, B) 
Following methamphetamine (0.3 mg kg
-1
) + placebo, C) Following 
methamphetamine (0.3 mg kg
 -1
) + Calabadion 2 (65 mg kg
-1
), and D) Following 
methamphetamine (0.3 mg kg
-1
) + Calabadion 2 (130 mg kg
-1
). Calabadion dose-
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General Experimental Details. Starting materials were purchased from 
commercial suppliers and were used without further purification or were prepared 
by literature procedures. Compound 1 and 5 were prepared according to literature 
procedures.
40
 The synthesis of IV-3a, IV-3b, and IV-3c from dibromoalkanes and 
hydroquinone were performed by procedures similar to those reported in the 
literature.
106,107
 The characterization data matches the reported data.  
Melting points were measured on a Meltemp apparatus in open capillary tubes 
and are uncorrected. IR spectra were measured on a JASCO FT/IR 4100 




NMR spectra were measured on Bruker 
spectrometers operating at 400 or 600 MHz for 
1
H and 200 MHz for 
13
C NMR. 
ITC data was collected on a Malvern Microcal PEAQ-ITC instrument. Mass 















Synthetic Procedures and Characterization Data.  
Compound IV-3a. A mixture of hydroquinone (17.55 g, 159 mmol) 
and potassium carbonate (44.00 g, 318 mmol) in acetonitrile (123 
mL) was heated to 85 °C under N2. 1,2-dibromoethane (3.0 g, 1.4 mL, 15.9 
mmol) was added dropwise and the reaction was stirred for 12 h. The reaction 
mixture was cooled and filtered and the filtrate was evaporated under reduced 
pressure to obtain the crude solid product. This crude product was washed with 
water (375 mL) and recrystallized from ethanol (75 mL) to obtain IV-3a as an off 
white solid (0.51 g, 2.1 mmol, 13%). M.p. = 212-214 °C. IR (ATR, cm
-1
): 
3365w(br), 2943 w, 1512s, 1452m, 1373w, 1268w, 1211s, 1109 m, 1081w, 
1070m, 1011w, 954s, 943w, 831s, 813m, 756s. 
1
H NMR (600 MHz, DMSO): 
8.91 (s, 2H), 6.78 (d, J = 8.9, 4H), 6.67 (d, J = 8.9, 4H), 4.14 (s, 4H). 
13
C NMR 
(150 MHz, DMSO, 1,4-dioxane as internal reference): δ 151.4, 151.2, 115.8, 
115.5, 67.0. High-Res MS (ESI): m/z 245.0825 ([M - H]
-
), calculated for 
C14H13O4
-
 245.0814.  
 Compound IV-3b. A mixture of hydroquinone (27.10 g, 246 
mmol) and potassium carbonate (68.00 g, 492 mmol) in acetonitrile 
(190 mL) was heated to 85 °C under N2. 1,6-dibromohexane (6.0 g, 
3.8 mL, 24.6 mmol) was added dropwise and the reaction was stirred for 12 h. 
The reaction mixture was cooled and filtered and the filtrate was evaporated under 
reduced pressure to obtain the crude solid product. This crude product was 







IV-3b as an off white solid (3.66 g, 12.3 mmol, 50%). M.p. = 178-180 °C. IR 
(ATR, cm
-1
): 3381w(br), 2944w, 2866w, 1506s, 1477m, 1452m, 1395w, 1374m, 
1299m, 1221s, 1167m, 1104s, 1072w, 1022s, 826s, 806m, 763s, 732m. 
1
H NMR 
(600 MHz, DMSO): 8.85 (s, 2H), 6.72 (d, J = 8.9, 4H), 6.65 (d, J = 8.9, 4H), 3.84 
(t, J = 6.5, 4H), 1.72-1.63 (m, 4H), 1.48-1.38 (m, 4H).  
13
C NMR (150 MHz, 
DMSO): δ 151.5, 151.1, 115.7, 115.3, 67.8, 28.8, 25.4. High-Res MS (ESI): m/z 
301.1443 ([M - H]
-
), calculated for C18H21O4
-
 301.1440. 
Compound IV-3c. A mixture of hydroquinone (11.00 g, 100 
mmol) and potassium carbonate (27.64 g, 200 mmol) in acetonitrile 
(160 mL) was heated to 85 °C under N2. 1,10-dibromodecane (3 g, 2.2 mL, 10 
mmol) was added dropwise and the reaction was stirred for 12 h. The reaction 
mixture was cooled and filtered and the filtrate was evaporated under reduced 
pressure to obtain the crude solid product. This crude product was washed with 
water (500 mL) and recrystallized from ethanol (75 mL) to obtain IV-3c as an off 
white solid (1.18 g, 3.3 mmol, 33%). M.p. = 146-148 °C. IR (ATR, cm
-1
): 
3420w(br), 2931w, 2917w, 2852w, 1509m, 1473w, 1451w, 1395w, 1371w, 
1299w, 1227s, 1168w, 1104w, 1048w, 822s, 767s. 
1
H NMR (600 MHz, DMSO): 
8.84 (s, 2H), 6.72 (d, J = 8.9, 4H), 6.65 (d, J = 8.9, 4H), 3.82 (t, J = 6.5, 4H), 1.64 
(p, J = 7.0, 4H), 1.41-1.34 (m, 4H), 1.34-1.22 (m, 8H).  
13
C NMR (150 MHz, 
DMSO, 1, 4-dioxane as internal reference): δ 151.5, 151.0, 115.6, 115.3, 67.8, 












Compound IV-4a. A solution of 1,3-propanesultone (1.34 g, 11 
mmol) in 1,4-dioxane (11 mL) was added to a solution of IV-3a 
(1.2 g, 4.1 mmol)  in aqueous sodium hydroxide solution (10 
wt%, 9 mL). This mixture was stirred at RT for 12 h and then filtered to collect 
the crude solid. The crude product was washed with acetone (30 mL). The filtered 
solid was dissolved in hot water (15 mL) and precipitated with ethanol (30 mL) to 
obtain the off white solid IV-4a (1.91 g, 3.6 mmol, 87%). M.p. > 300 °C. IR 
(ATR, cm
-1
): 3422w(br), 2942w, 2520w, 1512s, 1450w, 1285w, 1201s, 1053s, 
943m, 758m, 734m. 
1
H NMR (600 MHz, D2O): 7.06-7.04 (m, 4H), 7.04-7.02 (m, 
4H), 4.37 (s, 4H), 4.18 (t, J = 6.3, 4H), 3.13-3.09 (m, 4H), 2.25-2.18 (m, 4H).  
13
C 
NMR (150 MHz, D2O, 1, 4-dioxane as internal reference): δ 152.3, 151.9, 115.9, 
115.8, 67.0, 66.7, 47.3, 23.8. High-Res MS (ESI): m/z 489.0882 ([M - 2Na + H]
-
), 
calculated for C20H25O10S2 
- 
489.0889. 
Compound IV-4b. A solution of 1,3-propanesultone (7.7 g, 63 
mmol) in tetrahydrofuran (152 mL) was added to a solution of 
IV-3b (7.6 g, 25.2 mmol)  in aqueous sodium hydroxide solution 
(10 wt%, 76 mL). This mixture was stirred at RT for 12 h and then filtered to 
collect the crude solid. The crude product was washed with acetone (200 mL). 
The filtered solid was dissolved in hot water (100 mL) and precipitated with 
ethanol (200 mL) to obtain the off white solid IV-4b (11.5 g, 9.4 mmol, 77%). 
M.p. > 300 °C. IR (ATR, cm
-1
): 2941w, 2905w, 2870w, 1508s, 1475m, 1399w, 









H NMR (600 MHz, D2O): 7.03-7.00 (m, 4H), 7.00-6.98 (m, 4H), 4.16 (t, J 
= 6.3, 4H), 4.07 (t, J = 6.5, 4H), 3.13-3.07 (m, 4H), 2.24-2.16 (m, 4H), 1.82-1.75 
(m, 4H), 1.54-1.50 (m, 4H).  
13
C NMR (150 MHz, DMSO, 1,4-dioxane as internal 
reference): δ 152.6, 115.3, 115.3, 67.8, 67.1, 48.0, 28.8, 25.4. High-Res MS 
(ESI): m/z 545.1519 ([M - 2Na +H]
-
), calculated for C24H33O10S2
-
 545.1515. 
Compound IV-4c. A solution of 1,3-propanesultone (1.00 g, 
8.25 mmol) in tetrahydrofuran (20 mL) was added to a solution 
of IV-3c (1.2 g, 3.3 mmol) in aqueous sodium hydroxide 
solution (10 wt%, 10 mL). This mixture was stirred at RT for 12 h and then 
filtered to collect the crude solid. The crude product was washed with acetone (30 
mL). The filtered solid was dissolved in hot water (15 mL) and precipitated with 
ethanol (30 mL) to obtain the off white solid IV-4c (1.0 g, 1.6 mmol, 47%). M.p. 
> 300 °C. IR (ATR, cm
-1
): 2935w, 2924w, 2853w, 1508s, 1475m, 1396w, 1289w, 
1217s, 1115w, 1046s, 1029s, 827s, 768m, 731m. 
1
H NMR (600 MHz, DMSO, 1, 
4-dioxane as internal reference):  7.02-7.00 (m, 4H), 7.00-6.98(m, 4H),  4.14 (t, J 
= 6.3, 4H), 4.05 (t, J = 6.5 4H), 3.11-3.07 (m, 4H), 2.23-2.16 (m, 4H), 1.74 (p, J = 
6.9, 4H), 1.44 (p J = 7.3, 4H), 1.39-1.30 (m, 8H). 
13
C NMR (150 MHz, DMSO, 1, 
4-dioxane as internal reference): δ 152.6, 152.6, 115.3, 115.2, 67.8, 67.1, 48.0, 






 Compound IV-2a. Compound IV-4a (1.8 g, 3.4 mmol) was added to a 







mL) and acetic anhydride (130 mL). This solution was stirred and heated 
at 70 °C for 3 h. The reaction mixture was cooled to room temperature, 
treated with methanol (130 mL), and the solvent was removed under 
reduced pressure to obtain the crude product. The crude product was 
washed three times with a mixture of water (50 mL) and acetone (100 
mL). The dark orange colored solid obtained was loaded onto a Dowex® 
1X2 chloride form, 200-400 mesh ion exchange resin (50 g). The column 
was eluted with increasing concentrations of hydrochloric acid (HCl) 
starting from plain water (750 mL) to 6M HCl (750 mL) to 12 M HCl 
(300 mL). The eluted fractions were analyzed by 
1
H NMR and the almost 
pure compound IV-2a was obtained in the fractions eluted with 12 M HCl. 
This fraction was dried under reduced pressure and washed with a mixture 
of water and methanol (1:1, v/v, 100 mL). Finally, the solid obtained was 
dissolved in water and the pH of the solution was adjusted to 7 using 
aqueous sodium hydroxide (1M). The solvent was removed under reduced 
pressure and the solid was further dried under high vacuum to obtain pure 
IV-2a as a light orange solid (0.72 g, 0.56 mmol, 33%). M.p. > 300 °C. IR 
(ATR, cm
-1
): 3447w (br), 1712s, 1466s, 1422m, 1377m, 1317s, 1228s, 
1182s, 1084m, 1036s, 974m, 926w, 794s, 760s, 731m. 
1
H NMR (600 
MHz, D2O): 7.17 (d, J = 9.0, 2H), 7.05 (d, J = 9.0, 2H), 5.63 (d, J = 15.5, 
2H), 5.54 (d, J = 15.5, 2H), 5.50 - 5.42 (m, 8H), 5.26 (d, J = 16.4, 2H), 
4.47 (d of d, J = 5.4, 2H), 4.33 (d, J = 16.4, 2H), 4.31 (d, J = 15.7, 2H), 







3.13 (m, 4H), 2.30 (p, J = 7.2, 4H), 1.76 (s, 6H), 1.75 (s, 6H).
 13
C NMR 
(125 MHz, D2O, 1, 4-dioxane as internal reference): δ 157.3, 156.2, 155.9, 
154.5, 151.2, 149.0, 127.8, 127.7, 117.9, 113.9, 81.4, 78.9, 77.4, 71.1, 
70.8, 70.6, 68.0, 51.8, 47.9, 47.7, 47.5, 35.4, 33.7, 24.2, 14.5, 13.7. High-
Res MS (ESI): m/z 616.1650 ([M - 2Na]
2-




Compound IV-2b. Compound 
IV-4b (2.0s g, 3.4 mmol) was 
added to a solution of IV-5 (1.3 
g, 1.7 mmol) in a mixture of 
trifluoroacetic acid (130 mL) 
and acetic anhydride (130 mL). This solution was stirred and heated at 70 
°C for 3 h. The reaction mixture was cooled to room temperature, treated 
with methanol (130 mL), and the solvent was removed under reduced 
pressure to obtain the crude product. The crude product was washed three 
times with a mixture of water (50 mL) and acetone (100 mL). The dark 
orange colored solid obtained was loaded onto a Dowex® 1X2 chloride 
form, 200-400 mesh ion exchange resin (50 g). The column was eluted 
with increasing concentrations of hydrochloric acid (HCl) starting from 
plain water (750 mL) to 6M HCl (750 mL) to 12 M HCl (300 mL). The 
eluted fractions were analyzed by 
1
H NMR and the almost pure compound 







was dried under reduced pressure and washed with a mixture of water and 
methanol (1:1, v/v, 100 mL). Finally, the solid obtained was dissolved in 
water and the pH of the solution was adjusted to 7 using aqueous sodium 
hydroxide (1M). The solvent was removed under reduced pressure and the 
solid was further dried under high vacuum to obtain pure IV-2b as a light 
yellow solid (0.30 g, 0.56 mmol, 13%). M.p. > 300 °C. IR (ATR, cm
-1
): 
3449w (br), 2939w, 1719s, 1464m, 1425w, 1378w, 1314m, 1230m, 
1181m, 1084m, 1036s, 972m, 924w, 797s, 758m, 730w. 
1
H NMR (600 
MHz, D2O): 7.01-6.96 (m, 4H), 5.72 (d, J = 15.4, 1H), 5.57 (d, J = 15.4, 
1H), 5.56 (d, J = 15.7, 2H), 5.53 (d, J = 15.7, 2H), 5.46 (d, J = 9.0, 2H), 
5.38 (d, J = 16.4, 2H), 5.37 (d, J = 9.1, 4H), 5.25 (d, J = 16.4, 2H), 4.36 
(d, J = 15.7, 2H), 4.32 (d, J = 16.4, 2H), 4.24 – 4.12 (m, 4H), 4.22 (d, J = 
15.7, 2H), 4.16 (d, J = 15.4, 1H), 4.13 (d, J = 16.4, 2H), 4.03 (d, J = 15.4, 
1H), 3.90-3.76 (m, 4H), 3.127-3.11 (m, 4H), 2.34-2.23 (m, 4H), 1.76 (s, 
6H), 1.75 (s, 6H), 1.39-1.26 (m, 4H), 1.18-1.09 (m, 2H), 1.05-0.95 (m, 
2H). 
13
C NMR (150 MHz, DMSO, 1, 4-dioxane as internal reference): δ 
156.0, 155.2, 154.8, 154.1, 150.2, 150.0, 127.8, 126.6, 113.9, 113.5, 77.3, 
76.9, 70.5, 70.2, 69.5, 68.5, 64.6, 59.2, 48.5, 48.3, 48.0, 35.7, 34.4, 28.0, 






  Compound IV-2c. Compound 







added to a solution of IV-5 (1.0 g, 1.3 mmol) in a mixture of 
trifluoroacetic acid (100 mL) and acetic anhydride (100 mL). This solution 
was stirred and heated at 70 °C for 3 h. The reaction mixture was cooled 
to room temperature, treated with methanol (100 mL), and the solvent was 
removed under reduced pressure to obtain the crude product. The crude 
product was washed three times with a mixture of water (50 mL) and 
acetone (100 mL). The dark orange colored solid obtained was loaded 
onto a Dowex® 1X2 chloride form, 200-400 mesh ion exchange resin (50 
g). The column was eluted with increasing concentrations of hydrochloric 
acid (HCl) starting from plain water (750 mL) to 6M HCl (750 mL) to 12 
M HCl (300 mL). The eluted fractions were analyzed by 
1
H NMR and the 
almost pure compound IV-2c was obtained in the fractions eluted with 12 
M HCl. This fraction was dried under reduced pressure and washed with a 
mixture of water and methanol (1:1, v/v, 100 mL). Finally, the solid 
obtained was dissolved in water and the pH of the solution was adjusted to 
7 using aqueous sodium hydroxide (1M). The solvent was removed under 
reduced pressure and the solid was further dried under high vacuum to 
obtain pure IV-2c as an off white solid (0.47 g, 0.34 mmol, 26%). M.p. > 
300 °C. IR (ATR, cm
-1
): 3435w (br), 2930w, 1721s, 1463s, 1425m, 
1378m, 1313m, 1230s, 1181s, 1085m, 1037s, 972m, 924w, 823m, 797s, 
757m, 731m. 
1
H NMR (600 MHz, D2O): 7.10-6.98 (m, 4H), 5.72 (d, J = 
15.2, 1H), 5.64 (d, J = 15.2, 1H), 5.59 (d, J = 15.7, 2H), 5.56 (d, J = 15.7, 







(d, J = 16.5, 2H), 4.31 (d, J = 15.7, 2H), 4.23 (d, J = 15.7, 2H), 4.20 – 4.08 
(m, 11H), 4.06 (d, J = 15.2, 1H), 4.01-3.93 (m, 2H), 3.28-3.09 (m, 4H), 
2.35-2.22 (m, 4H), 1.78 (s, 6H), 1.74 (s, 6H), 1.58-1.46 (m, 2H), 1.40-1.27 
(m, 2H), 1.12-0.93 (m, 4H), 0.91-0.75 (m, 6H), 0.75-0.65 (m, 2H). 
13
C 
NMR (150 MHz, DMSO, 1, 4-dioxane as internal reference): δ 156.1, 
155.2, 154.6, 154.0, 150.2, 150.1, 128.1, 114.0, 113.6, 113.5, 77.5, 76.4, 
70.7, 70.4, 69.8, 68.6, 64.6, 59.2, 48.4, 48.3, 48.2, 34.7, 34.5, 28.5, 27.2, 
27.1, 25.6, 24.2, 16.6, 15.7.High-Res MS (ESI): m/z 672.2341 ([M - 
2Na]
2-

























C NMR spectra (150 MHz, DMSO, 1, 4-dioxane as internal 











































C NMR spectra (150 MHz, DMSO, 1, 4-dioxane as internal 






















C NMR spectra (150 MHz, D2O, 1, 4-dioxane as internal 






















C NMR spectra (150 MHz, DMSO, 1, 4-dioxane as internal 






















C NMR spectra (150 MHz, DMSO, 1, 4-dioxane as internal 






















C NMR spectra (125 MHz, D2O, 1, 4-dioxane as internal 






















C NMR spectra (150 MHz, DMSO, 1, 4-dioxane as internal 





















C NMR spectra (150 MHz, DMSO, 1, 4-dioxane as internal 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-6, b) 
IV-1, c) an equimolar mixture of IV-6 and IV-1 (1 mM), and d) a 2:1 mixture of 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-6, b) 
IV-2a, c) an equimolar mixture of IV-6 and IV-2a (0.5 mM), and d) a 2:1 mixture 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-6, b) 
IV-2b, c) an equimolar mixture of IV-6 and IV-2b (0.5 mM), and d) a 2:1 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-6, b) 
IV-2c, c) an equimolar mixture of IV-6 and IV2c (0.3 mM), and d) a 2:1 mixture 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-7, b) 
IV-1, c) an equimolar mixture of IV-7 and IV-1 (1 mM), and d) a 2:1 mixture of 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-7, b) 
IV-2a, c) an equimolar mixture of IV-7 and IV-2a (0.5 mM), and d) a 2:1 mixture 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-7, b) 
IV-2b, c) an equimolar mixture of IV-7 and IV-2b (0.5 mM), and d) a 2:1 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-7, b) 
IV-2c, c) an equimolar mixture of IV-7 and IV-2c (1 mM), and d) a 2:1 mixture 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-8, b) 
IV-1, c) an equimolar mixture of IV-8 and IV-1 (1 mM), and d) a 2:1 mixture of 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-8, b) 
IV-2a, c) an equimolar mixture of IV-8 and IV-2a (0.5 mM), and d) a 2:1 mixture 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-8, b) 
IV-2b, c) an equimolar mixture of IV-8 and IV-2b (0.5 mM), and d) a 2:1 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-8, b) 
IV-2c, c) an equimolar mixture of IV-8 and IV-2c (0.3 mM), and d) a 2:1 mixture 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-9, b) 
IV-1, c) an equimolar mixture of IV-9 and IV-1 (0.5 mM), and d) a 2:1 mixture 











H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-9, b) 
IV-2a, c) an equimolar mixture of IV-9 and IV-2a (0.5 mM), and d) a 2:1 mixture 












H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-9, b) 
IV-2b, c) an equimolar mixture of IV-9 and IV-2b (0.5 mM), and d) a 2:1 













H NMR spectra recorded (600 MHz, RT, D2O) for a) IV-9, b) 
IV-2c, c) an equimolar mixture of IV-9 and IV-2c (0.25 mM), and d) a 2:1 











H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-10, b) 
IV-1, c) an equimolar mixture of IV-10 and IV-1 (1 mM), and d) a 2:1 mixture of 












H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-10, b) 
IV-2a, c) an equimolar mixture of IV-10 and IV-2a (0.5 mM), and d) a 2:1 











H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-10, b) 
IV-2b, c) an equimolar mixture of IV-10 and IV-2b (0.5 mM), and d) a 2:1 










H NMR spectra recorded (400 MHz, RT, D2O) for a) IV-10, b) 
IV-2c, c) an equimolar mixture of IV-10 and IV-2c (1 mM), and d) a 2:1 mixture 







Determination of Ka between various hosts guests using Isothermal Titration 
Calorimetry (ITC). 
  
All ITC experiments were conducted in the 200 μL working volume of the sample 
cell of the PEAQ ITC instrument.  We used an injection syringe of 40 μL 
capacity. In each case, the host and guest solutions were prepared in a 20 mM 
NaH2PO4 buffer (pH 7.4). The sample cell was filled to capacity (200 μL) with the 
host solution and the guest solution was titrated in (first injection = 0.4μL, 
subsequent 18 injections = 2 μL). In case of Figures IV-S40, IV-S42, IV-S48 and 
IV-S56 two sets of 19 injections were concatenated to obtain the binding 
isotherm. In case of Figure IV-S50 the first set of 19 injections was followed by 
an additional 26.4 μL of titrant added over 10 injections and these 29 injections 
were concatenated to obtain the binding isotherm. The binding data was fitted 








Figure IV-S39. a) Plot of DP vs time from the titration of IV-1 (70.5 μM) with 
guest IV-6 (0.507 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 8.7 ± 0.05 kcal/mol, N 







Figure IV-S40. a) Plot of DP vs time from the titration of IV-2a (100 μM) with 
guest IV-6 (2.00 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 3.94 ± 0.35 kcal/mol, 








Figure IV-S41. a) Plot of DP vs time from the titration of IV-2b (0.1 mM) with 
guest IV-6 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 5.5 ± 0.06 kcal/mol, 








Figure IV-S42. a) Plot of DP vs time from the titration of IV-2c (0.2 mM) with 
guest IV-6 (1.01 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 
to a 1:1 binding model (Ka = (2.3 ± 0.2) × 10
4









Figure IV-S43. a) Plot of DP vs time from the titration of IV-1 (0.1 mM) with 
guest IV-7 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 8.2 ± 0.04 kcal/mol, N 








Figure IV-S44. a) Plot of DP vs time from the titration of IV-2a (0.1 mM) with 
guest IV-7 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 













Figure IV-S45. a) Plot of DP vs time from the titration of IV-2b (0.2 mM) with 
guest IV-7 (2.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 8.62 ± 0.02 kcal/mol, 









Figure IV-S46. a) Plot of DP vs time from the titration of IV-2c (0.1 mM) with 
guest IV-7 (2.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 6.0 ± 0.23 kcal/mol, N 








Figure IV-S47. a) Plot of DP vs time from the titration of IV-1 (0.1 mM) with 
guest IV-8 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 10.5 ± 0.03 kcal/mol, N 









Figure IV-S48. a) Plot of DP vs time from the titration of IV-2a (0.25 mM) with 
guest IV-8 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 11.3 ± 0.19 kcal/mol, 









Figure IV-S49. a) Plot of DP vs time from the titration of IV-2b (0.1 mM) with 
guest IV-8 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 9.5 ± 0.05 kcal/mol, N 








Figure IV-S50. a) Plot of DP vs time from the titration of IV-2c (0.1 mM) with 
guest IV-8 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 8.5 ± 0.12 kcal/mol, N 









Figure IV-S51. a) Plot of DP vs time from the titration of IV-1 (0.1 mM) with 
guest IV-9 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 7.1 ± 0.05 kcal/mol, N 








Figure IV-S52. a) Plot of DP vs time from the titration of IV-2a (0.15 mM) with 
guest IV-9 (0.99 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 4.48 ± 0.48 kcal/mol, 








Figure IV-S53. a) Plot of DP vs time from the titration of IV-2b (0.10 mM) with 
guest IV-9 (0.99 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 3.86 ± 0.17 kcal/mol, 








Figure IV-S54. a) Plot of DP vs time from the titration of IV-2c (0.50 mM) with 
guest IV-9 (5.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 6.47 ± 0.06 kcal/mol, 









Figure IV-S55. a) Plot of DP vs time from the titration of IV-1 (0.1 mM) with 
guest IV-10 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 9.0 ± 0.09 kcal/mol, N 










Figure IV-S56. a) Plot of DP vs time from the titration of IV-2a (0.25 mM) with 
guest IV-10 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 6.9 ± 0.07 kcal/mol, N 








Figure IV-S57. a) Plot of DP vs time from the titration of IV-2b (0.1 mM) with 
guest IV-10 (0.78 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 




, ΔH = - 9.6 ± 0.04 kcal/mol, 








Figure IV-S58. a) Plot of DP vs time from the titration of IV-2c (0.1 mM) with 
guest IV-10 (1.0 mM) in 20 mM NaH2PO4 buffer (pH 7.4); b) plot of the ΔH as a 
function of molar ratio. The solid line represents the best non-linear fit of the data 
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